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Abstract 
 
Intracellular Ca2+ and adenosine triphosphate (ATP) are the key elements 
needed for stimulant-evoked exocytotic enzyme secretion from pancreatic 
acinar cells. Physiological Ca2+ signals consist of repetitive spikes confined to 
the secretory granule region, which stimulate ATP production; whereas 
sustained global cytosolic Ca2+ elevations - toxic Ca2+ signals decrease ATP 
levels and cause necrosis leading to the inflammation of the pancreas - acute 
pancreatitis (AP), a life-threatening disease currently without specific therapy. 
The work presented in this thesis focuses on the mechanisms underlying the 
development of pancreatitis evoked by L-asparaginase and the potential ways 
to intervene asparaginase-associated pancreatitis (AAP). Asparaginase is an 
essential element of the chemotherapy regimen in the successful treatment of 
acute lymphoblastic leukaemia (ALL), the most common childhood cancer. But 
asparaginase treatment can lead to AAP, which is a side-effect of ALL 
treatment occurring in about 5–10% of cases. Following AP, further treatment 
with asparaginase is withheld to prevent recurrence of AP; however, 
withholding scheduled asparaginase is associated with a potential increase in 
ALL relapse. Understanding the pathogenesis of AAP could lead to effective 
therapies for this complication, potentially reducing toxicity and allowing 
re-exposure to continue treatment with asparaginase. 
 
The data presented within this thesis show that asparaginase induces 
pathological intracellular (cytosolic and mitochondrial) Ca2+ responses in 
pancreatic acinar cells. We have found that asparaginase caused enlarged 
Ca2+ entry and substantially reduced Ca2+ extrusion in pancreatic acinar cells 
due to decrease in intracellular ATP levels. Asparaginase-induced pathology 
highly depends on proteinase activated receptor 2 (PAR2) and its inhibition 
largely prevents both toxic Ca2+ signals and necrosis. We tested the effects of 
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pharmacological blockade of Ca2+ release activated Ca2+ (CRAC) entry by the 
specific Ca2+ channel inhibitor GSK-7975A and found that GSK-7975A 
markedly reduced asparaginase-induced cytosolic Ca2+ overload and also 
protected effectively against the development of necrosis. Interestingly, energy 
supplements such as adding pyruvate, fructose or galactose to pancreatic 
acinar cells had profound protective effects on asparaginase-induced Ca2+ 
overload, ATP loss and necrosis in vitro while removal of glucose did not have 
a significant effect. Galactose feeding had a dramatic protective effect in an 
asparaginase-induced in vivo model of AP.  
 
This study provides fresh evidence for the pathogenic mechanisms of AAP and 
the results presented in this thesis demonstrate both Ca2+ and ATP are pivotal 
for the pathophysiological process by which asparaginase treatment of ALL 
may cause AAP. We can therefore conclude that combining inhibition of Ca2+ 
overload with energy supplements could be a potential therapeutic approach 
to protect against AAP. This would prevent AP development and allow 
continuous of the successful asparaginase treatment during ALL childhood 
cancer treatments. 
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Chapter 1 
 
Introduction 
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The Pancreas 
 
Anatomy and histology 
The pancreas both as an organ and a seat of disease was generally ignored in 
ancient times. This may be due to the location of the gland hidden in the 
retroperitoneum. A Greek anatomist and surgeon Herophilus (335–280 BC) 
who is considered the Father of Scientific Anatomy firstly identified the 
pancreas in about 300 BC (1). However, this organ was named by an eminent 
Greek physician and anatomist Rufus of Ephesus in about 100 AD (2).  
Etymologically, the term ‘pancreas’ is a Latin adaptation of Greek παγκρέας 
(παγ = all or whole, and κρέας = flesh, or meat), which is most probably 
because the pancreas contains no bones or cartilage and has a relatively 
uniform composition and consistency (3). Andreas Vesalius (1514 - 1564) gave 
a fair description of the pancreas. According to his work, the Fabric of the 
Human Body, the pancreas seems to be a gland impressed with the vessels 
running through it. However, he had no knowledge about the ductal system of 
the pancreas and considered it as a protective organ for the stomach (4). In 
1642, Johann George Wirsung (1589 - 1643), a German anatomist and the 
prosector to Veslingus in Padua, described the main duct of the human 
pancreas (5). 
 
The pancreas (Figure 1.1) is the crucial digestive and endocrine glandular 
organ in humans. The pancreas is a lobulated and retroperitoneal gland about 
15 cm long and 5 cm wide with its weight ranging from 82 to 117 g. It lies 
transversely behind the stomach and across the lumbar spine (L1 - L2) within 
the left upper abdominal cavity. The pancreas is partitioned into four parts: the 
head, the neck, the body and the tail. The head of the pancreas is embedded 
in the duodenal loop. The neck is located anterior to the superior mesenteric 
artery. The body of the pancreas, the largest part of the pancreas lying behind 
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the base of the stomach, is located between the neck and the tail and its 
posterior edge is close to the lumbar region. The tail of the pancreas is a thin 
and narrow part to the left of the pancreas and ends abutting the spleen. The 
tail of pancreas is surrounded by serosa whereas the other parts are found in 
the retroperitoneal space. Therefore the lesions of the pancreas are often deep 
and hidden. The pancreas has two main ducts: the main pancreatic duct (duct 
of Wirsung) and the accessory pancreatic duct (duct of Santorini). Pancreatic 
juice passes from the pancreatic duct through the ampulla of Vater into the 
duodenum. 
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Figure 1.1 Anatomy of the pancreas in the human body.  
In humans, the pancreas is located in the abdominal cavity. It lies transversely behind 
the stomach and is close to the duodenum. The pancreas consists of four parts: the 
head, the neck, the body and the tail. (Modified from Cid-Arregui A and Juarez V, 
World J Gastroenterol, 2015) (6) 
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The pancreas is a dual-function gland which has both exocrine and endocrine 
functions (Figure 1.2). The endocrine functions are performed by the islets of 
Langerhans, formed by the clustered endocrine cells, which are small, 
island-like structures within the exocrine pancreatic tissue that account for only 
1–2% of the entire organ (7). There are approximately one million islets in the 
pancreas and a larger number of smaller islets distributed in the head and a 
smaller number of larger islets distributed in the tail of the pancreas (8). 
Although these cell clusters distributed among the pancreatic acinar cells vary 
in size and shape, they still can be classified by their secretory functions: β 
cells, accounting for 65–80% of the total islet cells, secrete insulin while the 
less common glucagon-secreting α cells are also involved in blood glucose 
homeostasis (9). The other cells include δ cells which secrete somatostatin 
(regulates/stops α and β cells) (10) and PP cells which secrete pancreatic 
polypeptide (regulates pancreatic secretion) (11,12). Recently, it has been 
reported that ghrelin is expressed in human fetal pancreas and pancreatic 
ghrelin cells may therefore constitute a new islet cell type (13). Although there 
is similarity of islets cellular composition among different species, their 
cytoarchitecture differs greatly (Figure 1.3). Generally, islets are primarily 
composed of β-cells located in the center surrounded by other cell types in the 
periphery in rodents (14). However, it is indicated that human islets show close 
interconnection between α- and β-cells (15). In contrast, the exocrine functions 
are performed by the pancreatic acini and the duct. The pancreatic duct cells, 
mainly centroacinar cells, secrete pancreatic juice which contains water (up to 
97%) and bicarbonate ions. Bicarbonate ions, which are alkaline, can 
neutralize the acidic chime and gastric acid in the duodenum in order to 
provide the most suitable pH conditions for digestive enzymes working in the 
small intestine. The pancreatic acinar cells filled with secretory granules 
secrete the digestive enzymes (trypsinogen, chymotrypsinogen, lipase, 
amylase and other digestive enzymes). Pancreatic secretions drain to the 
main pancreatic duct via intralobular ducts and then pass directly into the 
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duodenum. Once this pancreatic fluid is released in the intestine, the enzyme 
enterokinase activates trypsinogen to trypsin. Subsequently, trypsin cleaves 
the rest of the trypsinogen, chymotrypsinogen as well as other precursor 
digestive enzymes to their active forms. The exocrine functions of pancreas 
are controlled by humoral regulation (via the hormones gastrin, cholecystokinin 
(CCK) and secretin) and, to a lesser extent, the parasympathetic nerves. 
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Figure 1.2 Anatomical organization and histology of the pancreas.  
The endocrine function of the pancreas is regulated by the pancreatic islets of 
Langerhans involving the secretion of various hormones to the blood stream from 
different cell types. The exocrine function is mediated by acinar cells that secrete 
digestive enzymes into the duodenum via the pancreatic duct. The micrograph shows 
the histology of pancreatic tissue. (Adapted from Röder PV et al, Exp Mol Med, 2016) 
(9) 
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Figure 1.3 Microanatomy of the pancreas of the human and the mouse.  
Microscopic anatomical structure of the pancreas reveals cell cytoarchitecture of the 
islets of Langerhans within the pancreas are markedly different between the human 
(A) and the mouse (B). (Modified from Dolenšek J et al, Islets, 2015) (16) 
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Endocrine function 
The endocrine function of the pancreas is well known for its association with 
diabetes mellitus. The first written record of diabetes was in the Egyptian 
manuscript around 1500 BC. The term diabetes mellitus, reflecting the fact that 
the urine of those affected had a sweet taste, was first used by the Greek 
physician Aretaeus of Cappadocia (fl. 1st century AD). In 1889, Joseph von 
Mering and Oskar Minkowski found that removing the pancreas from dogs 
caused diabetes (17–19). This provided the first clue that diabetes is 
associated with the pancreas and the pancreas plays a key role in maintaining 
glucose homeostasis. In 1893, Laguesse suggested that the islet cells 
(described by Langerhans in 1869) of the pancreas were the histologic 
components involved in the pancreas of the patient with diabetes (20). All 
these studies had a breakthrough in 1921. Frederick Grant Banting and 
Charles Herbert Best discovered insulin when they recovered dogs that was 
nearly moribund in diabetic coma by injecting an extract from the pancreatic 
islet cells of healthy dogs (21). Together with James Collip and John Macleod, 
they purified the hormone insulin from bovine pancreases so that it could be 
used clinically for the first time to treat a patient with diabetes (22). Many 
scientists have received the Nobel Prize for diabetes-related investigations 
since 1923 because of their outstanding achievement in the study of diabetes 
and related aspects of glucose metabolism (Table 1.1). 
 
The endocrine functions of the pancreas are diverse and involve various 
different hormonal regulations. These functions are largely dissociated with 
those of exocrine pancreas and will not be discussed further here. 
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Table 1.1 Nobel Prizes for Diabetes-Related Research. (Modified from Polonsky 
KS, N Engl J Med, 2012) (22) 
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Exocrine function 
In the mid-17th century, Regnier de Graaf (1641 - 1673) collected and 
investigated the pancreatic juice by way of using a hollow quill of a goose 
feather to cannulate the pancreatic duct of a dog (23). This was the initial study 
on discovering the role of the pancreas in digestive processes. However, the 
groundbreaking discovery of the digestive function of the pancreas was made 
by the great French physiologist Claude Bernard (1813 - 1878), who is called 
‘‘one of the greatest of all men of science’’. He showed the pancreatic juice 
could emulsify fatty foods as well as contribute to the absorption of fats (24,25). 
He also demonstrated the digestive action of the pancreas to convert starch 
into sugar (25). This was the first evidence that confirmed the digestive 
function of the pancreas and what had been believed was that digestion did 
not take place entirely within the stomach. During the 19th century, Ivan 
Petrovich Pavlov (1849 - 1936), a Russian physiologist known primarily for his 
work in classical conditioning, indicated that pancreatic secretion was 
mediated by neural reﬂexes via a special pancreatic fistula in the dog (26). 
However, Ernest Starling and his brother-in-law William Bayliss demonstrated 
the hormone secretin was involved in pancreatic secretion (27–29). This 
proved the existence of a hormonal mechanism in regulating secretory 
function of the pancreas (30). In 1943, Harper and Raper reported the second 
hormone named pancreozymin (PZ) was able to stimulate the secretion of 
pancreatic enzymes (31). Subsequently, Jorpes and Mutt found that 
cholecystokinin (CCK) and PZ possessed the same biological properties of 
stimulating pancreatic enzyme secretion (32). The actions from PZ (the 
release of enzymes from the pancreas) and CCK (the contraction of the 
gallbladder, which forces bile into duodenum) were recognized as coming from 
one protein. Nowadays, it is generally solely known and used as CCK. It is now 
clear that pancreatic secretion is controlled by both neural and hormonal 
regulation (7,33,34). 
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An acinus and its draining ductule are the fundamental functional unit of the 
exocrine pancreas (Figure 1.4). As mentioned above, the small ductal cells- 
centroacinar cells secrete a HCO3
- rich fluid, when stimulated by the hormone 
secretin (Table 1.2). An acinus is defined as any cluster of cells is assembled 
by many-lobed sacs, that is, pancreatic acinus is organized by several hundred 
acinar cells. These cells are linked by multiple gap junctions which regulates 
both direct chemical and electrical intercellular communication between cells 
(35–37). The main function of the pancreas which is the exocrine function 
consisting of synthesis and secretion of digestive enzymes (Table 1.2). The 
exocrine secretory process is composed of six successive steps: synthesis, 
segregation, intracellular transport, concentration, intracellular storage, and 
discharge (38). Cellular organelles e.g. ribosomes, endoplasmic reticulum 
(ER), Golgi apparatus and zymogen granules etc. are involved in this process 
within pancreatic acinar cell from the initiation of digestive enzymes production 
to the destination of triggering exocytosis. Generally, the secretory process of 
exocytosis is regulated by cytosolic Ca2+ concentration ([Ca2+]i) and this 
process is known as “stimulus-secretion coupling” (39–43), whereby only a low 
level of initial stimulus could be enormously amplified via multiple messengers 
in this chain reaction and resulted in cellular stimulation. In human, CCK is one 
of the most important hormone stimulating pancreatic acinar cells for 
secretion.  
 
Table 1.2 The exocrine functions of pancreas. 
Secretory component Cell type Primary stimuli 
Water and bicarbonate ions Centroacinar cells Secretin 
Digestive enzymes Acinar cells CCK 
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Figure 1.4 The exocrine pancreas.  
The functional unit of the exocrine pancreas is composed of an acinus and its draining 
ductule. An acinus surrounding a central lumen open to the duct system is formed by 
pancreatic acinar cells. Pancreatic acinar cells synthesize, store and secrete digestive 
enzymes for the digestion and absorption of food in the small intestine. Digestive 
enzymes are secreted through the apical membrane of the acinar cell into small 
intercalated ducts that are directly connected to increasingly larger intralobular ducts 
that join the main pancreatic duct. (Modified from Logsdon CD & Ji B, Nat Rev 
Gastroenterol Hepatol. 2013) (44) 
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Pancreatic acinar cells  
Pancreatic acinar cell is the dominant (up to 80%) cell type in the pancreas 
(45). Each pancreatic acinar cell is polarized with two visible areas: basolateral 
pole and apical pole (Figure 1.5). They are separated by the mitochondrial belt 
which can buffer the calcium from the apical pole to the basolateral pole. The 
basolateral pole is larger (even up to 90% of the cell volume) than the apical 
pole, and the majority of the endoplasmic reticulum (ER) is located in 
basolateral area. However, the endoplasmic reticulum can penetrate the 
mitochondria belt into the apical pole (46). The apical pole contains zymogen 
granules (ZGs) where digestive proenzymes are stored. 
 
The main function of acinar cells is to secrete digestive enzymes in response 
to eating food. This secretion is mediated by acetylcholine (ACh), which is 
released from the endings of the vagus nerve, and the circulating hormone 
cholecystokinin (CCK). The secretion process itself takes place by exocytosis. 
The granule membrane fuses with the apical (luminal) cell membrane and 
subsequently the opening pole of the granule allows zymogens to move into 
the acinar lumen. The acinar cells and the small ducts each secrete a neutral 
Cl- rich and a HCO3
- rich fluid respectively so that the zymogens can move 
from the duct system into the gut. 
 
As was previously mentioned, ACh or CCK activates pancreatic acinar cells to 
secrete an isotonic NaCl-rich pancreatic acinar juice containing a majority of 
enzymes and precursor enzymes. Enzymes contained in the acinar fluid are 
active α-amylase, lipases and colipase as well as various other enzymes (e.g. 
collagenase, elastase, phospholipase A and ribonuclease), whereas the 
precursor enzymes are trypsinogen, chymotrypsinogen and 
procarboxypeptidases. These protease precursors are activated in the small 
intestine, initiated by intestinal enzyme enterokinase converts trypsinogen to 
15 
 
trypsin. Subsequently, trypsin activates trypsinogen auto-catalytically and also 
activates the other precursors. The neutral pancreatic acinar juice, containing 
these enzymes and enzyme precursors, is delivered to intercellular 
cananiculus where it is mixed with the HCO3
- rich fluid secreted by the 
centroacinar cells in response to stimulation with the hormone secretin (47–
49). 
 
The physiological functions of pancreatic acinar cells are controlled by calcium 
(50). Different patterns of cytosolic calcium responses differentiate between 
physiology and pathology. Physiological concentration of ACh and CCK evoke 
either small cytosolic [Ca2+]i oscillations, which are often confined only to 
apical area of the cell or global calcium waves that originate in the apical area 
and spread toward the basolatoral area (51,52). The ACh or CCK receptors at 
the basolateral plasma membrane receive stimuli for secretion (such as ACh 
or CCK) leading to the generation of a second messenger response, which in 
turn liberates calcium from the intracellular stores (53–55). 
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A 
 
B 
 
Figure 1.5 Structure of pancreatic acinar cell. 
(A) Transmitted light image from the confocal microscope shows typical triplet 
pancreatic acinar cells isolated from mouse pancreas. Scale bar is 10 μm. (B) 
Schematic illustration of the pyramid-shaped structure of a pancreatic acinar cell. The 
basolateral pole contains most of the ER; zymogen granules are stored in the apical 
pole. (Adapted from Gerasimenko JV et al, J Cell Sci, 2006) (55) 
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Early studies indicated that the ER was the principal intracellular calcium store 
and the neurotransmitters ACh as well as the circulating hormone CCK elicited 
Ca2+ release from the ER (56–58). Intracellular water soluble messenger 
inositol 1,4,5-trisphosphate (IP3) was discovered and shown releasing Ca
2+ 
from the ER in permeabilized pancreatic acinar cells (59,60). Although the 
original discovery of IP3-evoked Ca
2+ release was found on pancreatic acinar 
cells, it is still difficult to understand why physiological Ca2+ signals occur 
specifically in the apical granular pole, which contains mostly ZGs and little ER 
(52,61–64). Ca2+ tunnel experiments answered this question and 
demonstrated that Ca2+ taken up at the base of the cell into the ER could 
diffuse easily in the ER lumen and reach the apex via thin ER extensions 
penetrating deeply into the granular area between the ZGs (65,66). Moreover, 
the highest concentration or the most sensitive IP3 receptors (IP3Rs) are 
concentrated in the apical region of the pancreatic acinar cells (67,68). Ca2+ 
release in mouse pancreatic acinar cells is dependent on IP3 receptor (IP3R) 
subtypes 2 and 3, which can replace by each other (69). Knockout both 
subtypes resulted in no IP3-mediated Ca
2+ release(69). Physiologically Ca2+ 
signals occurring in the apical pole are essential for activating exclusive Cl- 
channels present in the apical membrane-Ca2+-activated Cl- channels, which 
are important for acinar fluid and the exocytotic enzyme secretion (70). The 
mitochondria distributed in a very specific manner in the acinar cells. Due to 
their ability to soak up Ca2+, the localization of mitochondria could preventing 
the spread of cytosolic Ca2+ signals from the apical pole into the basal part of 
the cell containing the nucleus (71,72). 
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Intracellular calcium signalling in the 
pancreas 
 
Calcium as an intracellular messenger 
In 1959, Nobel laureate Otto Loewy described the role of calcium ions in the 
organism by a witty remark: “Ja Kalzium, das ist alles!” (73). It is undeniable 
that calcium ion (Ca2+) is one of the most important signaling molecules in the 
organism and impact nearly every aspect of cellular life (74,75). External 
stimuli can be transduced by calcium signalling into cells, which participate in 
the regulation of heartbeat, muscle contraction, neuronal signal coding, gene 
expression, fertilisation, cell growth and proliferation, cell migration, cell cycle, 
apoptosis, cancer, neurogenesis, learning and memory as with synaptic 
plasticity and other physiological and pathological processes (76–85). Studies 
on calcium signalling cover the understanding of the different levels of calcium 
signalling dynamics from cellular organelles to whole organs. The regulatory 
mechanism of calcium signalling is complex and it can interact with other 
signal networks in the cell. As calcium signalling integrates a wide range of 
cellular functions, the transduction of calcium signalling mediated by Ca2+ is 
under strict control, that is, Ca2+ acts on different types of cells under tight 
spatiotemporal coordination with different intensities to regulate their specific 
physiological functions. 
 
Ca2+ plays an important role in cell signal transduction, this is because protein 
and enzyme conformations and their interactions are regulated by [Ca2+]i. 
[Ca2+]i change can trigger the alteration of shape and charge in proteins and 
enzymes, which can affect function. There are two primary calcium signalling 
transduction pathways in eukaryotic cells. The first pathway is that Ca2+ enters 
into cells directly through the activated ion channels and transporters. The 
other one is that Ca2+ acts as a second messenger indirectly involved in signal 
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transduction. For example, extracellular stimulus or signals can activate 
calcium signalling by G protein-coupled receptor (GPCR) (86). G protein 
coupled receptors (GPCRs), also known as seven-transmembrane domain 
receptors, are expressed in all eukaryotic cells (87), and more than 2,000 
genes in the human genome that encode GPCRs, which are the largest 
receptor molecule superfamily on the cell membrane (88). Structurally, G 
proteins are heterotrimeric complexes which made up of alpha (α), beta (β) 
and gamma (γ) subunits (89). There are a large number of diseases 
associated with GPCRs, and about 40% of modern drugs target GPCRs (90).  
 
Normally, resting cytoplasmic [Ca2+] is maintained at about 100 nM in 
eukaryotic cells, which is 20,000-fold lower than extracellular [Ca2+] (74). To 
maintain this low concentration, various membrane calcium pumps, channels 
and exchangers are involved in coordinating this very tight control process.  
ATPase pumps are responsible for cytosolic Ca2+ clearance, that is, 
sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) pumps Ca2+ into the 
endoplasmic reticulum (ER) or plasma membrane Ca2+ ATPase (PMCA) 
pumps push Ca2+ out of the cell (Figure 1.6). Both SERCA and PMCA are P 
type ATPases which remove two or one Ca2+ per ATP hydrolyzed, respectively 
(91). In many cell types, the Na+/Ca2+ exchanger (NCX) is an antiporter 
membrane protein that removes calcium from cells, which exchanges one Ca2+ 
for the import of three Na+ (92). Interestingly, the high-affinity, low-capacity 
PMCA pumps are effective at maintaining low [Ca2+]i over long durations, 
whereas the low-affinity, high-capacity NCX make the rapid adjustments 
needed during generation of action potentials in excitable cells (92–95). Hence, 
they complement each other for internal [Ca2+] homeostasis. However, NCX 
only plays a minor role in pancreatic acinar cells (96,97). Notably, calmodulin 
can substantially increase both Ca2+ binding affinity and pump rate of PMCA 
(98,99). 
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Figure 1.6 Maintaining Ca2+ homeostasis and using Ca2+ gradients for 
signalling. 
Cytoplasmic [Ca2+] is maintained at about 100 nM in pancreatic acinar cells by 
extrusion mainly via two transporters: sarco/endoplasmic reticular Ca2+ ATPase 
(SERCA) and plasma membrane Ca2+ ATPase (PMCA). The Na+/Ca2+ exchanger 
(NCX), a major secondary regulator of [Ca2+]i imports three Na
+ in exchange for the 
export of one Ca2+. However, NCX plays a very minor role in cytosolic Ca2+ clearance 
in pancreatic acinar cells. Intracellular Ca2+ depolarizes pancreatic acinar cells by 
activating Cl− channels in the apical pole. (Modified from Clapham DE, Cell. 2007) 
(74) 
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Generally, exocytosis is activated by a rise in the [Ca2+]i (100–102). In excitable 
cells e.g. nerve and endocrine cells; exocytosis is normally trigged by Ca2+ 
entry via special voltage-activated Ca2+ channels in the plasma membrane. 
Membrane depolarization leads to voltage-gated channels open, which is 
caused by action potentials (103). However, pancreatic acinar cell is 
electrically non-excitable cell and not able to fire action potentials. Therefore, 
stimulus-secretion coupling is dependent on Ca2+ release from intracellular 
stores to the cytosol (104). It has been established that the initial secretory 
response of pancreatic acinar cell to ACh or CCK stimulation is independent of 
extracellular Ca2+, whereas external Ca2+ is indispensable for sustained 
secretion (43). Ca2+ release from the intracellular Ca2+ stores into the cytosol 
inevitably activates Ca2+ pumps in the plasma membrane, which causes 
intracellular Ca2+ from the internal stores to be extruded to the extracellular 
fluid (105). In this situation, a well-known process known as store-operated 
Ca2+ entry is activated by the reduction of [Ca2+] in the intracellular stores (106). 
Such Ca2+ signalling is transmitted from the stores to the plasma membrane 
activating store-operated channels (SOCs) that allow Ca2+ entry (107). Due to 
this store-operated Ca2+ entry (SOCE) the sustained secretory response is 
maintained in pancreatic acinar cells during prolonged stimulation. 
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Calcium release 
Pancreatic acinar cell is the typical polarized mammalian exocrine gland cell, 
which is particularly attractive and generally accepted model for studying Ca2+ 
transport processes. This is because characteristic subcellular distributions of 
cellular organelles including the ER, the mitochondria and the ZGs, etc. which 
are crucial to Ca2+ signalling, facilitated the description of intracellular Ca2+ 
signalling events (46,55,71,108,109). It has been well established that a rise in 
[Ca2+]i of pancreatic acinar cells is stimulated by either ACh or CCK. 
Physiological concentration of the neurotransmitter ACh or the hormone CCK 
evokes small [Ca2+]i oscillations, which are the typical Ca
2+ signal pattern 
consists of repetitive [Ca2+]i spikes often confined only to apical (granular) area 
of the cell. Whereas increasing the stimulating agonist concentration causes 
global calcium waves that originate in apical area and spread toward the 
basolatoral area.  
 
There are two major signal transduction pathways (Figure 1.7) that induce 
Ca2+ release in pancreatic acinar cells: 1) nervous (ACh) stimulation mediated 
Ca2+ release; 2) hormonal (CCK) stimulation initiated Ca2+ release. Both the 
physiological stimulants act on the outside of the acinar plasma membrane 
(53,54). ACh binds to muscarinic M3 receptors (110) activating phospholipase 
C (PLC) via G protein pathway leading to the breakdown of 
phosphatidylinositol 4,5-bisphosphate (PIP2). The subsequent generation of 
inositol 1,4,5-trisphosphate (IP3), an intracellular messenger, regulates the 
release of Ca2+ from the ER (59). CCK acts on high affinity CCK1 receptors in 
the basolateral plasma membrane (111,112). Subsequently, the enzyme 
ADP-ribosyl cyclase is activated by a yet unknown mechanism to form two 
separate messengers: nicotinic acid adenine dinucleotide phosphate (NAADP) 
and cyclic ADP-ribose (cADPR) (113). The three messengers, IP3, cADPR, 
and NAADP, can liberate Ca2+ from the ER by activating IP3Rs (69) and RyRs 
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(114,115), respectively. 
 
 
 
Figure 1.7 Local Ca2+ signalling in a pancreatic acinar cell. 
Calcium signalling events occur at the plasma membrane. Two receptor pathways are 
shown. CCK interaction with CCK1 receptors results in activation of the cytosolic 
enzyme ADP-ribosyl cyclase, which generates cADPR and NAADP. ACh binding to 
muscarinic M3 receptors activates, via interaction with a classical trimeric G protein, 
phospholipase C (PLC) generating the messenger IP3. cADPR and NAADP activate 
RyRs, whereas IP3 activates IP3Rs in intracellular stores to release Ca
2+ from ER. 
(Adapted from Petersen OH & Tepikin AV, Annu Rev Physiol. 2008) (50) 
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In fact, physiological Ca2+ signals occurring in the apical granular area are not 
only due to Ca2+ release from ER, but also Ca2+ could be released from ZGs 
and other acid pools in the apical pole (Figure 1.8) (55,116,117). It was shown 
that both IP3 and cADPR - derived from nicotinamide adenine dinucleotide 
(NAD) can release Ca2+ on isolated ZGs (118). Subsequently, in a study of 
permeabilized pancreatic acinar cells it was shown that IP3, cADPR and 
NAADP - derived from Nicotinamide adenine dinucleotide phosphate (NADP) 
can all liberate Ca2+ from both the ER and ZGs dominated acid pools in the 
apical granular area (55,119). It also has been demonstrated that IP3 activates 
IP3Rs, whereas cADPR or NAADP activates RyRs to release Ca
2+ on isolated 
nuclei surrounded by several layers of ER (120). Recently, it has been 
reported that NAADP-evoked Ca2+ release from endosomes/lysosomes is 
completely dependent on functional two-pore channels (TPCs) (121,122), and 
particularly on TPC2 (123). This triggers Ca2+-induced Ca2+ release (CICR) by 
RyR subtypes 1 and 3 occurring from the zymogen granules and the ER (123).  
 
Cytosolic Ca2+ signals elicited by physiological agonists – ACh or CCK or 
directly by one of the intracellular messengers - IP3, cADPR or NAADP are 
always initiated in the apical pole of pancreatic acinar cells. This is because of 
the concentration of critical Ca2+ release channels in the apical pole rather 
than the concentration of agonist receptors in the apical membrane (51,124). 
Mapping of intracellular CICR sites by local Ca2+ uncaging specifically in the 
apical pole demonstrated this point of view. CICR elicited in the apical pole 
produce a Ca2+ wave progressing toward the basolatoral area. However, local 
Ca2+ uncaging failed to trigger CICR at the base (51). As shown in Figure 1.8, 
CICR depends on both functional Ca2+ release channels - IP3Rs and RyRs. 
The RyRs seem uniformly distributed throughout the cell (125), which differs 
from the distribution of IP3Rs (67,68). CICR is central to all types of Ca
2+ signal 
generation in the acinar cells. Therefore, either IP3R or RyR antagonists can 
abrogate Ca2+ spiking regardless of the primary stimulus (126). 
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Figure 1.8 Ca2+ release from two types of intracellular stores in the apical pole. 
Two principal stores are located in the apical pole : 1) ER with SERCA (red) and both 
IP3Rs as well as RyRs; 2) acidic organelles with a vacuolar H
+ pump (black), also with 
both IP3Rs and RyRs. Ca
2+ release from both the ER and the acidic Ca2+ store can be 
induced by Ca2+-releasing messengers: IP3, cADPR, or NAADP. Ca
2+-induced Ca2+ 
release (CICR) is the physiological cytosolic Ca2+ signal generated by interaction 
between the two stores as well as interaction between RyRs and IP3Rs. (Adapted 
from Petersen OH & Tepikin AV, Annu Rev Physiol. 2008) (50) 
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The reason for Ca2+ signalling events in intact acinar cells are complex is that 
repetitive Ca2+ spiking requires co-operation between functionally active IP3Rs 
and RyRs (80). In other words, Ca2+-mediated positive and negative 
interactions between IP3Rs and RyRs are functionally important for 
physiological Ca2+ signalling events generation. For example, intracellular Ca2+ 
release induced by an increase of IP3 concentration will subsequently activate 
RyRs inducing further Ca2+ release. The rising phase of the cytosolic Ca2+ 
signal is initiated by this positive feed-forward effect. However, when [Ca2+]i 
reaches at a certain higher level, a further [Ca2+]i rise suppress opening of both 
IP3Rs and RyRs, which explains the falling phase of the spike by this negative 
feedback effect (127). 
 
The termination of Ca2+ signals has the same importance as their initiation. 
During sustained stimulation with ACh, plateau of elevated [Ca2+]i represents a 
delicate balance of Ca2+ entry through store-operated Ca2+ channels (SOCs) in 
the basal membrane (128,129) and Ca2+ extrusion mainly through Ca2+ pumps 
located in the apical plasma membrane (PMCA) (96,130). Discontinuation of 
supramaximal ACh stimulation immediately causes Ca2+ pump 
(SERCA)-mediated Ca2+ reuptake into the ER and a rapid reduction of [Ca2+]i 
back to the resting level (66). [Ca2+] in the ER ([Ca2+]ER) takes much longer to 
recover fully than [Ca2+]i (128). However, physiological concentrations of ACh 
or CCK cause small amounts of Ca2+ release from ER, which evoke the 
smallest and shortest cytosolic Ca2+ spikes, has proven to be impossible to 
decrease [Ca2+]ER during each spike (131). 
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Calcium entry and extrusion 
Although intracellular Ca2+ release from ER induced by physiological 
concentration of ACh or CCK for secretion is the primary event, Ca2+ entry and 
extrusion can simultaneously regulate the overall cellular Ca2+ homeostasis, 
which is essential for both physiology and pathology of pancreatic acinar cells. 
If any regulatory process of Ca2+ transport is out of control that would lead to 
cellular Ca2+ overload causing cell death (132–134). Therefore the plasma 
membrane must be relatively impermeable to Ca2+ and Ca2+ movement across 
the plasma membrane provides a clear example of the steady state [Ca2+]i in 
pancreatic acinar cells with extreme structural and functional polarization. In 
other words, PMCA is not only maintain a low [Ca2+]i, but also restore the low 
[Ca2+]i after a challenge-elicited [Ca
2+]i increase. Upon [Ca
2+]i of above 100 nM, 
Ca2+ extrusion is activated to adjust [Ca2+]i back to the resting level. Whereas, 
Ca2+ entry occurred predominantly across the basolateral membrane is 
responsible for refilling the ER (135). The process and transport mechanisms 
of Ca2+ entry and extrusion across the plasma membrane of pancreatic acinar 
cells is regulated by specific Ca2+ channels and pumps (Figure 1.9).  
 
As mentioned previously, unlike many electrically excitable cells, pancreatic 
acinar cells do not possess functional NCX. The process of Na+/Ca2+ 
exchange plays an important role in restoring a low [Ca2+]i following an action 
potential (92). However, the rate of Ca2+ extrusion following stimulation 
induced [Ca2+]i elevation in pancreatic acinar cells is not influenced by the 
removal of extracellular Na+ (96,105). Hence, the only mechanism for Ca2+ exit 
across the plasma membrane is via the PMCA (96,136). Interestingly, this 
pump is specifically concentrated in the apical plasma membrane rather than 
evenly distributed over the plasma membrane, and therefore physiological 
concentration of agonist-elicited [Ca2+]i above the basal level of 100 nM can 
activate PMCA-mediated Ca2+ extrusion in the apical pole and Ca2+ is mainly 
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extruded into the acinar lumen (137). The concentration of PMCA in the apical 
membrane is functionally important due to the initiation of intracellular Ca2+ 
release sites are in the apical pole. However, inappropriate Ca2+ entry across 
the basal membrane causes Ca2+ overload when pancreatic acinar cells are 
challenged by pathological stimulus, which PMCA cannot deal with this 
adequately because of its limited capacity (138). The half-maximal rate of 
calcium extrusion depends on [Ca2+]i of approximately 200 nM, but calcium 
extrusion mechanism was almost completely saturated when [Ca2+]i is above 
400 nM (139). Overall, pancreatic acinar cells solely depend on the PMCA to 
extrude excess intracellular Ca2+ in order to maintain and restore [Ca2+]i within 
the physiological range, but substantial cytosolic Ca2+ overload leads to 
malfunctioning of this well-functioning extrusion mechanism.  
 
It has been known that pancreatic acinar sustained secretory response and 
exocytosis is dependent on the presence of external Ca2+ (43,140). 
Physiological concentration of agonist-elicited Ca2+ spiking is primarily 
generated by internal Ca2+ release from intracellular stores, principally the ER 
(50,59). This does not increase Ca2+ permeability in the plasma membrane. 
Upon [Ca2+]i increases, plasma membrane Ca
2+ ATPases (PMCAs) are 
activated to extrude more cytosolic Ca2+ in order to maintain resting level of 
[Ca2+]i (130). Due to the rate of Ca
2+ extrusion of PMCA is faster than the rate 
of Ca2+ taken up into the ER by SERCA, [Ca2+]ER would be depleted gradually 
if there were not a mechanism of compensatory Ca2+ uptake from the external 
solution (141). It has been well established that Ca2+ release-activated Ca2+ 
(CRAC) channels, which are the one of the best known store-operated Ca2+ 
channels (SOCs), in the baso-lateral plasma membrane regulate this uptake 
mechanism (Figure 1.9) and CRAC channels have generally been well 
characterized (106,142–144). 
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Figure 1.9 Ca2+ transport-entry and extrusion in pancreatic acinar cell. 
Agonist stimulation liberate Ca2+ from endoplasmic reticulum (ER) store in the apical 
pole of the cell via the Ca2+ release channels-IP3 receptors (IP3Rs) and ryanodine 
receptors (RyRs). Ca2+ pumps (PMCAs) concentrated in the apical membrane 
extrude Ca2+ released from the apical part of the ER into the acinar lumen. Ca2+ 
enters through a store-operated channel (SOC) in the basal membrane and then is 
pumped into the ER by the Ca2+ pump (SERCA). Thereafter, Ca2+ flow through the 
lumenally continuous ER from the basal to the apical pole. (Adapted from Petersen 
OH et al, Trends Neurosci. 2001) (65) 
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Endowed with several particular biophysical features including high Ca2+ 
selectivity and a low unitary conductance (106), functional CRAC channels are 
assembled from two protein families: the Orai proteins and the stromal 
interaction molecule (STIM) proteins (145). Orai proteins form the ion channel 
pore and in particular Orai1 is the molecule responsible for Ca2+-selective 
CRAC channel currents, which is essential for CRAC channel activity 
(146,147). STIM proteins are functionally as the ER calcium sensors and 
activators of CRAC channels. Identification of stromal interaction molecule 1 
(STIM1) as the mammalian ER Ca2+ sensor (148,149) and Orai1/CRACM1 or 
Orai1/STIM1 as a component of the CRAC channel illuminate key steps in the 
molecular mechanism of SOCE (146,150–152). Following identification of 
Orai1 and STIM1 as two essential components of the CRAC channel, many 
works were turned to understand the pore architecture of the CRAC channel 
and the basis of Ca2+ influx. 
 
Orai1, as an essential component of the CRAC current (ICRAC) (153), was firstly 
identified by studies of T-lymphocytes using linkage analysis and positional 
cloning from patients with a severe combined immune deficiency (SCID) 
syndrome (146). Orai1 consists of four transmembrane domains (TM1-TM4) 
with cytosolic N- and C-termini, which contain STIM1 binding sites (Figure 
1.10). It has been demonstrated that Orai1 is an essential pore subunit and 
encodes the pore-forming subunit of the CRAC channel (154). The mutation of 
several acidic residues of Orai1 identified in TM1 (E106), TM3 (E190), and the 
TM1–TM2 (D110, D112, and D114) loop transforms ion selectivity or 
permeation (154–158). Subsequent study of the crystal structure of the 
Drosophila Orai channel revealed that this calcium influx channel is composed 
of a hexameric assembly of Orai subunits arranged in concentric layers around 
a central ion pore, which traverses the membrane and extends into the cytosol 
(159). It has been suggested that anion binding may play an important role in 
Orai gating mechanism that keeps the pore closed in the resting state (159). 
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However, this gating mechanism is still elusive and remains to be determined. 
 
STIM1 is a 77 kDa type I single-pass membrane protein with a luminal NH2 
terminus and a cytoplasmic COOH terminus localized predominantly in the ER 
membrane with multiple predicted protein interaction or signalling domains 
(Figure 1.10) (148,151,160). The ER luminal N-terminal region of STIM1 
contains two residing domains: an EF-hand (EF) calcium binding motif and a 
sterile α-motif (SAM). EF functionally acts as the protein with ER Ca2+ sensing 
(148,151) and SAM regulates STIM oligomerization (161). Although the 
cytosolic C-terminus is composed of several distinct coiled-coil (CC) domains 
and modules, the most critical region is a roughly 100 amino acid CRAC 
activation domain (CAD), which is also known as STIM-Orai activation region 
(SOAR) (155,162–166). CAD/SOAR binds to Orai, and a polybasic domain at 
the extreme COOH terminus interacts with the plasma membrane (PM) at 
ER-PM junctions, that is necessary and sufficient to activate ICRAC (163,167).   
 
In most cells, 75–85% of endogenous STIM1 is distributed in the ER 
membrane (168,169). Total internal reflection fluorescence (TIRF) and 
confocal microscopy showed that STIM1 is primarily localized throughout the 
ER when Ca2+ stores are full. Upon store depletion, STIM1 redistributes into 
discrete puncta near the plasma membrane (148,151,160,161,170–172). 
Electron microscopy revealed the most precise localization of STIM1, that is, 
the clustered STIM1 aggregates into puncta and accumulates within ER-PM 
junctions which are the junctional ER structures located 10-25nm from the 
plasma membrane (147,160). 
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Figure 1.10 Structure and functional domains of Orai1 and STIM1. 
Orai1 is a four times membrane-spanning Ca2+-selective channel with four 
transmembrane domains (TM1-TM4) and C and N termini directed to the cytoplasm. 
STIM1 is a single-transmembrane protein localized primarily in the ER membrane. 
The organization of the major predicted domains include EF-hand followed by a sterile 
α-motif (SAM) in the N terminus directed to the luminal side, and coiled-coil domains 
1-3 (CC1-3), which harbor CAD/SOAR, proline-serine-rich domain (P/S), and 
lysine-rich domain (K-rich) on the cytosolic side in the C terminus. (Modified from 
Lewis RS, Nature. 2007) (145) 
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Based on identification of structural functional domain organization of STIM 
and Orai, the mechanism of the molecular choreography of SOCE has been 
well established (142,173,174). The activation process of SOCE by store 
depletion is highly dynamic and dependent on the redistribution of STIM and 
Orai in the cell (Figure 1.11). Under the physiological condition of the resting 
state of the cells, STIM1 and Orai1 diffuse and mobilize throughout the ER and 
plasma membrane, respectively (148,151,161,163,175–177). In resting cells 
with replete Ca2+ stores, Ca2+ is bound to EF-hand domain forming a stable 
complex with the SAM domain on the luminal side. After ER store depletion, 
Ca2+ dissociates from the EF-hand and lead to the homogeneous distribution 
of clustered STIM1 accumulate in the ER-PM junctions and aggregates into 
puncta (50,142,145,148,160,176). The sites of Orai/STIM interaction are 
ER-PM junctions where STIM1 binding to Orai1 enhance the local 
concentration of STIM1 near Orai1, leading to rapid and efficient CRAC 
channel opening to trigger Ca2+ entry. This process is reversible only if Ca2+ is 
refilled in the ER store. In this scenario, EF-hand domain binds Ca2+ and 
facilitates the complex formation with SAM domain again, which results in 
deactivation of Orai (176,178,179). 
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Figure 1.11 Molecular mechanism of store-operated Ca2+ entry. 
The diagram depicts the process of store-operated Ca2+ entry. At resting level of 
[Ca2+]ER, Ca
2+ is binding EF-hand on the luminal side which maintain STIM in inactive 
state. Upon store depletion, Ca2+ dissociate from EF-hand domain, which triggers a 
conformational change of STIM and then STIM translocate and accumulate to ER-PM 
junctions by diffusion in the ER membrane. At the junctions, CAD/SOAR of STIM 
interacts and activates channels composed of Orai subunits via electrostatic 
interaction, thereby lead to opening of Orai1 Channels and Ca2+ entry. (Modified from 
Shen WW & Demaurex N, Biochem Soc Trans. 2012) (166) 
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Calcium signalling and mitochondrial functions 
It has been well established that the critical importance of intracellular Ca2+ 
and ATP for the regulation of exocytotic secretion in pancreatic acinar cells. 
Also, It is clear that exocytosis initiation is triggered by a rise in the [Ca2+]i in a 
various of cell types, but this would not happens if intracellular ATP is absence 
(180). Pancreatic acinar cells place special demands on the mitochondria to 
regulate Ca2+ homeostasis and energy requirements, in other words, 
mitochondria have evolved mechanisms for modifying energy production 
according to the change of [Ca2+]i. Therefore, mitochondria are extremely 
essential for physiological function of the acinar cells. In pancreatic acinar cells, 
mitochondria take up very specific positions and comprise three distinct groups: 
peri-granular, perinuclear, and sub-plasmalemmal (71,109,181,182). 
Quantification of mitochondrial density in different parts of the acinar cells of 
pancreatic tissue segments shows that the highest density of mitochondria are 
distributed in the peri-granular region, where mitochondria occupied 22.9 ± 
1.95 % of the area (Figure 1.12). The perinuclear area has a lower density of 
mitochondria, which occupied 9.07 ± 0.97% of the total area of the region, than 
the peri-granular (22.9 ± 1.95%) or peripheral areas (12.45 ± 0.78%), but 
nevertheless is significantly higher than in the non-specific regions (Figure 
1.12). 
 
Exocytosis requires ATP and ACh- or CCK-elicited Ca2+ signals activate the 
secretion process will therefore increase ATP consumption. Mitochondrial ATP 
production occurs by oxidative phosphorylation and the change of 
nicotinamide adenine dinucleotide (NADH) auto-fluorescence, which can serve 
as a valuable indicator of mitochondrial metabolism, in intact living cells can 
reflect this process (183,184). Cytosolic Ca2+ oscillations trigger repetitive rises 
in the NADH concentration, whereas a sustained elevation of [Ca2+]i only 
produce just one large NADH transient (185). This indicate that oscillating 
36 
 
[Ca2+]i responses induced by physiological agonist concentrations are more 
efficient than a sustained [Ca2+]i elevation caused by supramaximal agonist 
concentrations to stimulate mitochondrial energy production. It is remarkable 
that stimulation with physiological concentration of ACh or CCK, in spite of the 
increased ATP breakdown, does not decrease the cytosolic ATP concentration, 
but actually increase a modest ATP concentration, which occurs primarily in 
the mitochondria and depends on mitochondrial oxidative phosphorylation 
(186). When mitochondrial oxidative phosphorylation is inhibited, 
neurotransmitter/hormone stimulation cause a decrease in the cellular ATP 
level (186). Due to Ca2+ is taken up into the mitochondria via the mitochondrial 
calcium uniporter (MCU) (187–189), a rise in local [Ca2+] in the apical pole is 
quickly followed by a rise in the mitochondrial [Ca2+] ([Ca2+]m). Consequently, 
this stimulates three dehydrogenases in the Krebs cycle (190,191). Ca2+ 
release from the mitochondria is the relatively slow process, which ensures 
stimulation of mitochondrial ATP production. Therefore, stimulation of [Ca2+]m 
generates energy not only for fueling the secretion process but also for the 
processes responsible for extrusion of Ca2+ by PMCA through the apical 
membrane (137) and reuptake of Ca2+ via SERCA into the ER (Figure 1.13).   
 
The peri-granular mitochondria play a central role in stimulus-secretion and 
stimulus-metabolism coupling (182). They focus the cytosolic Ca2+ signals in 
the crucial apical region and optimize the opportunity for local ATP delivery 
aimed at securing the sustained exocytotic secretion. At the same time, the 
perigranular mitochondrial belt prevents invasion of Ca2+ signals initiated in the 
apical pole into the basal region as well as the nucleus. 
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Figure 1.12 The quantitative distribution of mitochondria in intact acinar cells of 
the pancreas. 
The bar charts illustrate the mean percentage area of specific region occupied by 
mitochondria in pancreatic acinar cells. Perigranular region (22.9 ± 1.95%), 
subplasmalemmal region (12.45 ± 0.78%) and perinuclear region (9.07 ± 0.97%) are 
the dominant areas for mitochondria located in the acinar cells. (Modified from 
Johnson PR et al, Cell Tissue Res. 2003) (181) 
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Figure 1.13 Primary functions of the three mitochondrial groups in pancreatic 
acinar cell. 
The diagram depicts the three different mitochondrial groups and their primary 
functions in pancreatic acinar cell. The peri-granular mitochondria are as a Ca2+ buffer 
barrier and supply ATP for secretory function in the apical region. The peripheral 
mitochondria provide ATP locally for the Ca2+ pump-mediated ER Ca2+ uptake. The 
perinuclear mitochondrial ring is likely to act as a barrier protected against invasion by 
Ca2+ waves for the nucleus. (Adapted from Petersen OH, Pflugers Arch. 2012) (182) 
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Acute Pancreatitis 
 
Epidemiology and aetiology of acute pancreatitis 
Acute pancreatitis (AP) (192,193) is a human disease which refers to an acute 
inflammatory disorder of the pancreas that frequently involves peripancreatic 
tissues and at times remote organ systems, usually occurred with abdominal 
pain and elevations of serum pancreatic enzymes. This disease is 
characterized by digestive proenzymes (i.e. trypsinogen) normally synthesized 
in the pancreatic acinar cells become active enzymes inside the cells, causing 
autodigestion of the pancreatic tissue and its surroundings and cell death 
(134,138,194). The prevalence of AP ranges from 13 to 45 per 100,000 people 
per year in the United States (195) and varies between 4.9 and 73.4 cases per 
100,000 worldwide (196). The incidence of acute pancreatitis has increased 
globally, including a large rise in pediatric populations (197–199). AP is the 
single most frequent cause of hospital admissions for gastrointestinal (GI) 
disorders with health care costs of $2.5 billion (200) and there are more than 
274,000 hospitalizations due to AP per year in the United States alone, which 
has increased by 12% from 2006 to 2012 (200,201). The mortality of AP is 
significant with more than 3000 deaths (1 out of 100,000) per year and 
approximately 1% in-hospital death (200,201). It has been widely accepted 
that repeated attacks of AP may cause chronic pancreatitis (CP) (Figure 1.14) 
(202–204). The annual incidence rate of CP is 5 to 12 per 100,000 people (205) 
and CP increases risk for development of pancreatic cancer (Figure 1.14), 
which is the second leading cause of death through gastrointestinal cancer 
and the fifth most common cause of cancer death, with extremely low 5-year 
survival rate which is about 3-4% (206,207). 
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Figure 1.14 The annual incidence of pancreatitis and pancreatic cancer. 
The sketch shows approximate incidence rates per 100,000 people per year and the 
arrow indicates the disease progression between benign (recurrent AP) and 
malignant (pancreatic cancer). (Adapted from Yadav D& Lowenfels AB, 
Gastroenterology. 2013) (195) 
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Table 1.3 lists the cause of acute pancreatitis. Biliary disease and alcohol 
abuse are the most common cause of acute pancreatitis, which accounts for 
up to 80% of cases of AP (138,202). Gallstones are a frequent cause of acute 
pancreatitis, which are believed that blockage of the pancreatic duct or 
obstruction of a common (bile-pancreatic) channel by the stone leads to reflux 
of bile into the pancreatic duct and cause pancreatic injury. Although the exact 
mechanisms due to gallstones initiate acute pancreatitis are presently not 
completely understood and the importance of this particular mechanism has 
been debated (208), it is nevertheless in any case that Ca2+-dependent cell 
death is caused by transporter-mediated bile acid uptake in pancreatic acinar 
cells in vitro (209).  
 
Alcohol abuse is the second leading cause of acute pancreatitis as well as a 
major cause of chronic pancreatitis. The risk of developing pancreatitis 
increases with excessive amounts of alcohol intake, but only a minority (<10%) 
of heavy drinkers develop pancreatitis (210). Alcohol appears to increase the 
sensitivity of the pancreas to injury caused by pancreatic stress (211). 
Prolonged alcohol use increases the risk for alcohol-related AP among 
persons who consumed more than 3 drinks daily over a period of more than 5 
years (212). Compared with those without a history of alcoholism, subjects in 
the heavy-drinking groups increase about 4-fold in the prevalence of 
pancreatitis (213). Alcohol use is the single most common cause of CP, which 
is a proven risk factor for pancreatic cancer (212). It has been reported that the 
higher frequency of alcohol-related pancreatitis in men than in women, which 
is due to genetic background (214). The mechanisms of alcohol-related AP or 
CP are complex and include both direct toxicity and immunologic effects (215).  
 
Other causes include drugs, hyperlipidemia, hypercalcemia, smoking, 
environmental toxins, morbid obesity, trauma, endoscopic retrograde 
cholangiopancreatography (ERCP) etc. (202,216–221). Genetic susceptibility 
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in a number of genes are associated with AP and CP, including mutations in 
the genes encoding cationic trypsinogen (PRSS1), serine protease inhibitor 
Kazal type 1 (SPINK1), cystic fibrosis transmembrane conductance regulator 
(CFTR), chymotrypsin C, calcium-sensing receptor (CaSR), and claudin-2 
(222,223).  
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Table 1.3 Causes of Acute Pancreatitis. (Modified from Forsmark CE et al, N 
Engl J Med, 2016) (192) 
Cause Approximate Frequency 
Gallstones 40% 
Alcohol 30% 
Hypertriglyceridemia 2–5% 
Genetic causes Not known 
Drugs <5% 
Autoimmune cause <1% 
ERCP 5–10% (among patients under-going 
ERCP) 
Trauma <1% 
Infection <1% 
Surgical complication 5–10% (among patients under-going 
cardiopulmonary bypass) 
Obstruction Rare 
Associated conditions Common (Diabetes, obesity, and 
smoking) 
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Clinical features and diagnosis of acute pancreatitis 
Typical clinical manifestations of patient who suffers acute pancreatitis are 
characterised by rapid onset of epigastric or left upper quadrant pain, which is 
usually described as non-specific pain constantly radiating to the back, chest, 
or flanks. This is generally associated with fever, nausea, vomiting and 
abdominal tenderness. The intensity of the pain is usually severe, but can be 
variable. Therefore, clinical manifestations of acute pancreatitis vary greatly 
and may present as mild, self-limiting abdominal discomfort, or acute abdomen 
and shock. Complications include agonizing pain, extensive inflammation and 
subsequent necrosis of pancreatic and surrounding tissue leads to systemic 
inflammatory response syndrome (SIRS) proceeding to multiple organ 
dysfunction syndrome (MODS) with long hospitalization and deaths in up to 5% 
of cases (202). According to a recent international consensus and the recently 
published revised classification, acute pancreatitis may be classified as mild, 
moderate or severe based on laboratory values and radiological imaging 
(Table 1.4) (224). 
 
Acute pancreatitis is diagnosed according to the Atlanta criteria if at least two 
of the following three criteria are fulfilled: clinical presentation (abdominal pain, 
often radiating to the back); serum lipase (or amylase) activity >3 times the 
upper limit of normal; or characteristic findings of acute pancreatitis on 
cross-sectional imaging - contrast-enhanced computed tomography (CECT) 
(Figure 1.15) (224). 
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Table 1.4 Definition of severity in acute pancreatitis (Revised Atlanta 
Classification 2012). (Modified from Banks PA et al, Gut. 2013) (224) 
 
Grades of severity Clinical features 
Mild No organ failure and no local or 
systemic complications 
Moderately severe Transient organ failure (<48 h) and/or 
local or systemic complications 
without persistent organ failure (>48 
h) 
Severe Persistent organ failure (>48 h): single 
organ failure or multiple organ failure 
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A 
 
B 
 
Figure 1.15 Contrast-enhanced computed tomography (CECT) imaging of acute 
pancreatitis. (Modified from Banks PA et al, Gut. 2013 and Wu BU & Banks PA, 
Gastroenterology. 2013) (217,224) 
(A) Acute interstitial oedematous pancreatitis. Peripancreatic fat stranding (arrows) is 
without an acute peripancreatic fluid collection. (B) Acute necrotic collection involves 
both the pancreas (large arrow) and peripancreatic tissue (arrowheads). 
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Pathogenesis of acute pancreatitis 
Over the past few decades, the investigations based on animal models have 
provided substantial evidence for revealing the molecular mechanisms 
underlying the pathobiologic responses of acute pancreatitis (202). The 
sequence of initiating molecular steps resulting in the pathophysiological 
processes of acute pancreatitis has reached the consensus that intracellular 
protease activation is crucial in the initiation and onset of acute pancreatitis 
(136,138). This process is triggered by intracellular calcium overload which is 
characterized by global sustained [Ca2+]i elevations (Figure 1.16) (225). This 
abnormal intracellular Ca2+ signalling depends on substantial release of Ca2+ 
from internal stores (ER and acidic store) followed by Ca2+ entry from the 
interstitial fluid, which can causes pancreatic acinar cell injury associated with 
abnormal intracellular enzyme activation, vacuolization and necrosis 
(134,194,226–228). It has also been found that intracellular vacuolization, 
which involves the zymogen granules being transformed into empty-looking 
vacuoles in the apical secretory granular pole, happens at the same time as 
protease activation (229). 
 
It is clear that intracellular Ca2+ is an essential signal molecule (second 
messenger) involved in the regulation of almost all cellular functions. In the 
pancreas, the neurotransmitter ACh and the hormone CCK control exocytotic 
secretion of digestive proenzymes and the crucial fluid secretion in acinar cells. 
These agonists, at physiological concentrations, generate repetitive 
short-lasting Ca2+ spikes which are physiological Ca2+ signals that are transient 
and mostly confined to the granule-containing apical pole of the cells (80,230). 
Exocytosis of digestive enzymes and fluid secretion are activated by the local 
oscillatory Ca2+ spikes (50). These findings originally based on studies of 
animal models, specifically the link between the presence of functional CCK 
receptors and Ca2+ signalling, subsequently have been confirmed by a 
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detailed study on the preparation of the normal portions of human pancreas 
(231,232). Supraphysiologic doses of various pathological stimuli causing 
acute pancreatitis elicit global and sustained elevations of [Ca2+]i, which can be 
fatal (Figure 1.17) (133,233,234). Instead of causing sustained secretion of 
proteases, such pathological Ca2+ signals lead to release of cathepsin-B (235) 
and intracellular trypsin activation (209,229,236–240). 
 
With regard to pathogenesis of AP, mitochondrial function associated with 
energy production is another very important aspect needs to be considered. As 
mention previously, three distinct groups of mitochondria are so specifically 
distributed in pancreatic acinar cells that production and demand of ATP are 
well tuned under physiological stimulation. Oscillating [Ca2+]i responses 
induced by physiological concentration of ACh or CCK cause repeated spikes 
of [Ca2+]m elevation that, in turn, activate Ca
2+-dependent Krebs-cycle 
dehydrogenases and stimulate mitochondrial ATP production (50,241), 
whereas a sustained [Ca2+]i elevation evoked by overstimulation with caerulin 
or a high concentration of CCK only elicits one initial burst of [Ca2+]m elevation 
and produce just one large NADH transient, which gives rise to one transient 
stimulation of ATP generation (50,185,186). In contrast, pathological 
stimulants implicated in pancreatitis such as non-oxidative alcohol metabolites 
- fatty acid ethyl esters and bile acids reduce both cytosolic and mitochondrial 
ATP (186,242). These pancreatitis-inducing stimulants induce calcium 
overload and ATP depletion in acinar cells, which eventually leads to necrosis 
(133,186). 
 
Mitochondrial permeability transition pore (MPTP) is a protein formed in the 
inner membrane of the mitochondria (IMM) under certain pathological 
conditions such as cardiac ischemia–reperfusion injury (243–246). The 
mitochondrial permeability transition is a phenomenon that the IMM undergo 
abrupt increase of its permeability to solutes, which manifest a cut-off to 
49 
 
molecules of about 1.5 kDa (247). MPTP opening enables free passage into 
the mitochondria of molecules of <1.5 kDa including protons. The proton 
gradient utilized by complex V of the respiratory chain is responsible for ATP 
synthesis. In addition, this electrochemical gradient across the IMM generate 
the charge imbalance which forms the basis of the inner mitochondrial 
transmembrane potential (Δψm). Therefore, the maintenance of the proton 
gradient is of the essence for cellular bioenergetics (248). Physiological 
stimulation may induce a transient loss of the Δψm (249), whereas long-lasting 
Δψm dissipation is often associated with cell death (250). This non-specific 
pore has been demonstrated as one of the crucial elements involved in 
mitochondrial pathophysiology of pancreatic injury (72,133,251,252). Calcium 
oscillations induced by stress and reactive oxygen species (ROS) can trigger 
MPTP opening and cell death (72,248,253,254). Mounting evidence suggests 
that Ca2+ overload and excessive generation of ROS as well as reactive 
nitrogen species (RNS) are involved in the pathophysiology of AP 
(133,202,255,256). 
 
Pancreatitis is characterized by cell death, which consists of two major types: 
apoptosis and necrosis (133,257). It is clear that Ca2+ signalling and 
bioenergetics regulate physiological and pathological processes in the 
pancreatic acinar cell and influence both apoptotic and necrotic cell death 
pathways (50,133,134,258). Although the pathobiologic processes of AP is 
complex and various different mechanisms has been implicated in the 
involvement of this diseases (193,202,215,222,259–266), intracellular Ca2+ 
signalling and ATP level are central to the control of cell life and death, and are 
fundamentally influence the severity of AP. 
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Figure 1.16 Pathological activity of Ca2+ overload in pancreatic acinar cells. 
(Modified from Gerasimenko OV & Gerasimenko JV. Pflugers Arch. 2012) (72) 
Pancreatitis-associated toxins can induce stress to acinar cells which leads to a 
pathological Ca2+ response in the cytosol, primarily due to Ca2+ release from internal 
stores followed by excessive Ca2+ entry and decreased Ca2+ extrusion. Ca2+ overload 
and together with ROS/RNS cause mitochondrial stress, MPTP opening and cell 
death. 
 
 
 
51 
 
 
 
Figure 1.17 Pathological events in the pathogenesis of AP. (Modified from Maléth 
J & Hegyi P, Philos Trans R Soc Lond B Biol Sci. 2016) (240) 
Pancreatitis-inducing stimulants (i.e. FAEEs and bile acids) release massive Ca2+ 
from intracellular stores and Ca2+ influx from the extracellular fluid occurred thereafter. 
This causes sustained [Ca2+]i elevation which leads to mitochondrial damage and 
activation of digestive enzymes in acinar cells. Toxic Ca2+ signals and ATP depletion 
impairs functional pumps in both acinar cells and ductal cells, which eventually trigger 
necrosis and AP.  
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Asparaginase 
 
Mechanism of action of asparaginase 
In 1953, John G. Kidd first observed that normal guinea-pig serum had 
antitumor activity which resulted in regression of transplanted lymphomas in 
both rat and mice (267). This initiated the discovery and development of 
asparaginase as a drug to treat cancer. L-Asparaginase was discovered as an 
anti-cancer drug since 1960s (268,269). Unlike other chemotherapy agents, it 
can be given as an intramuscular, subcutaneous, or intravenous injection 
without tissue irritation. L-Asparaginase has been found in different types of 
bacteria including Escherichia coli (E. coli), mycobacteria, Bacillus, Erwinia, 
Aspergillus, Salmonella, Pseudomonas, and Acinetobacter species. However, 
not all asparaginases show anti-cancer activity apart from E. coli and Erwinia 
chrysanthemi asparaginases (270). They are the only preparations available 
for clinical use. There are currently three main clinical formulations of 
asparaginase have been used so far: two are derived from E. coli, i.e. the 
native L-asparaginase, and the pegylated form of the native E. coli 
asparaginase (PEG-asparaginase) (271). The third is derived from Erwinia 
Chrysanthemi, referred to as Erwinia asparaginase (271,272).  
 
Given that most malignant transformed lymphoblasts are sometimes unable to 
synthesise sufficient asparagine for supporting their metabolism and growth, 
the depletion of the systemic asparagine pool caused by L-asparaginase via 
hydrolysis of L-asparagine to L-aspartic acid and ammonia will eventually lead 
to cell death (Figure 1.18) (273). However, resistant ALL leukaemic cells are 
not dependent on an exogenous L-asparagine source due to these cells 
contain L-asparagine synthetase, which converts aspartic acid into asparagine 
(Figure 1.18) (274,275). 
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Figure 1.18 Mode of action of L-asparaginase. (Modified from van den Berg H, 
Leuk Lymphoma. 2011) (270) 
This diagram shows the mechanism of L-asparaginase catalyzes the conversion of 
L-asparagine to L-aspartic acid in ALL.  
 
 
 
 
 
 
 
 
 
 
 
 
 
54 
 
Asparaginase toxicity 
Acute lymphoblastic leukaemia (ALL) is the most common cancer in childhood 
(276–278). Given that relatively high rate of survival of ALL on contemporary 
protocols (279), attention is now shifting onto treatment-related side effects 
(280). L-Asparaginase is an essential element of combination chemotherapy in 
the treatment of ALL (281–283). It is feasible as part of an intensive multiagent 
chemotherapeutic regimen in ALL and appears associated with improved 
outcomes including disease-free survival (DFS) (284–288). However, 
asparaginase itself like other chemotherapeutic agents has toxicities 
associated with hypersensitivity, pancreatitis, hyperglycemia, thrombosis, 
encephalopathy, and liver dysfunction etc. The most common reason for 
stopping treatment with L-asparaginase is acute pancreatitis named as 
asparaginase-associated pancreatitis (AAP) (216,289–295). This occurs in 
about 5–10% of the cases according to the consensus among the studies 
(290). AAP is the most frequent cause of discontinuing the asparaginase 
treatment, for re-exposure of asparaginase leads to recurrence of pancreatitis 
(289,296,297).  
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Aims of the study 
 
This study has the following aims; 
 
1) To investigate and understand the mechanisms and the pathophysiology 
underlying the development of L-asparaginase-associated pancreatitis. 
 
2) To determine the effects of calcium signalling and ATP in the 
pathogenesis of AAP in mouse models. 
 
3) To develop and test new ways of reducing the side-effects of 
asparaginase treatments for both in vitro and in vivo studies.  
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Chapter 2 
 
Materials and Methods 
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Materials 
 
Reagents and chemicals 
(±)-(3R*,4S*)-2-Oxo-4-phenyl-3-pyrollidinecarboxylic acid 
2-[1-(3-bromophenyl)ethylidene]hydrazide (AC 264613)，from TOCRIS, UK. 
Made up to a 50 mM stock solution in DMSO and frozen in 20 µl aliquots at 
-20°C. 
 
4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), from 
Sigma-Aldrich, UK. 
 
7-Chloro-5-(2-chlorophenyl)-1,5-dihydro-4,1-benzothiazepin-2(3H)-one 
(CGP-37157), Merck Millipore, UK. Made up to a 20 mM stock solution in 
DMSO and frozen in 30 µl aliquots at -20°C. 
 
Acetylcholine (ACh), from Sigma-Aldrich, UK. Made up to a 10 mM stock 
solution in water and frozen in 50 µl aliquots at -20°C. 
 
Asparaginase, from Abcam, UK. Made up to a 5000 IU/ml stock solution in 
water and and frozen in 40 µl aliquots at -80°C. 
 
Atropine, from Sigma-Aldrich, UK. Made up to a 2 mM stock solution in water 
and kept refrigerated at 4°C. 
 
Caffeine, from Sigma-Aldrich, UK. Made up to a 20 mM stock solution in water 
and kept refrigerated at 4°C. 
 
Calcium chloride (CaCl2), from Fluka, UK. 1 M stock solution kept in room 
temperature. 
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Carbonyl cyanide 3-chlorophenylhydrazone (CCCP), from Sigma-Aldrich, UK. 
Made up to a 10 mM stock solution in DMSO and frozen in 50 µl aliquots at 
-20°C. 
 
Cholecystokinin, from Sigma-Aldrich, UK. Made up to a 5 µM stock solution in 
water and frozen in 50 µl aliquots at -80°C. 
 
Collagenase, from Worthington, USA. Made up to a 222 IU/ml stock solution in 
NaHEPES buffer solution and frozen in 1 ml aliquots at -20°C. 
 
Cyclopiazonic acid (CPA), from Merck Millipore, UK. Made up to a 20 mM 
stock solution in DMSO and frozen in 40 µl aliquots at -20°C. 
 
D-galactose, from Sigma-Aldrich, UK. 
 
D-glucose, from Sigma-Aldrich, UK. 
 
Dimethyl Sulfoxide (DMSO), from Sigma-Aldrich, UK. Used as a diluent for 
hydrophobic chemicals. 
 
Ethanol, absolute, from Sigma-Aldrich, UK. 
 
Ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA), 
from Sigma-Aldrich, UK. Made up to a 100 mM stock solution in NaOH and 
kept refrigerated at 4°C. 
 
Fluo-4-AM, from Thermo Fisher Scientific, UK. Made up to a 2 mM stock 
solution in DMSO and frozen in 5 µl aliquots at -20°C. 
 
Formaldehyde, from Sigma-Aldrich, UK. 37 - 38% stock solution kept in room 
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temperature. 
 
Fructose, from Sigma-Aldrich, UK. 
 
FSLLRY-NH2 from TOCRIS, UK. Made up to a 1 mM stock solution in DMSO 
and frozen in 50 µl aliquots at -20°C. 
 
Fura-2-AM, from Thermo Fisher Scientific, UK. Made up to a 2 mM stock 
solution in DMSO and frozen in 5 µl aliquots at -20°C. 
 
GSK-7975A, from GlaxsoSmithKline, UK. Made up to a 10 mM stock solution 
in DMSO and frozen in 50 µl aliquots at -20°C. 
 
Magnesium chloride (MgCl2), from Sigma-Aldrich, UK. 
 
Magnesium Green (MgGreen), from Thermo Fisher Scientific, UK. Made up to 
a 2 mM stock solution in DMSO and frozen in 6 µl aliquots at -20°C. 
 
Oligomycin, from Merck Millipore, UK. Made up to a 5 mM stock solution in 
DMSO and frozen in 30 µl aliquots at -20°C. 
 
Palmitoleic acid ethyl ester (POAEE), from Cayman Chemical, UK. 
 
Phosphate-buffered saline (PBS), from Thermo Fisher Scientific, UK. 10X 
stock solution kept refrigerated at 4°C. 
 
Potassium Chloride (KCl), from Calbiochem, UK. 
 
Propidium iodide (PI), from Thermo Fisher Scientific, USA. 1 mg/ml stock 
solution kept refrigerated at 4°C. 
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Rhod-2-AM, from Thermo Fisher Scientific, UK. Made up to a 2 mM stock 
solution in DMSO and frozen in 10 µl aliquots at -20°C. 
 
Sodium Chloride (NaCl), from Sigma-Aldrich, UK. 
 
Sodium hydroxide (NaOH), from Sigma-Aldrich, UK. Made up to a 5 M stock 
solution in water and kept in room temperature. 
 
Sodium iodoacetate, from Sigma-Aldrich, UK. Made up to a 0.2 M stock 
solution in water and frozen in 200 µl aliquots at -20°C. 
 
Sodium pyruvate, from Sigma-Aldrich, UK. 100 mM stock solution kept 
refrigerated at 4°C. 
 
Taurolithocholic acid 3-sulfate (TLC-S), from Sigma-Aldrich, UK. Made up to a 
2 M stock solution in water and kept refrigerated at 4°C. 
 
Tetramethylrhodamine, methyl ester, Perchlorate (TMRM), from Thermo Fisher 
Scientific, UK. Made up to a 10 mM stock solution in DMSO and frozen in 50 µl 
aliquots at -20°C. 
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Equipment 
Analytical and Precision balances, from VWR International, UK. 
 
Autoclave, from Tuttnauer, UK. 
 
Calcium imaging system, from Scientifica, UK. 
 
Centrifuge, from Eppendorf, UK. 
 
Digital pH meter, from Infolab, UK. 
 
Dissecting instruments (scissors and tweezers), from stock in the laboratory. 
 
Fridges and biomedical freezers (-20°C and -80°C), from Bosch or Sanyo, UK. 
 
Integral Water Purification System - Milli-Q, from Merck Millipore, UK. 
 
Laser-scanning confocal microscope – Leica TCS SPE, from Leica, Germany. 
 
Magnetic Stirrers, from stuart-equipment, UK. 
 
Mini Centrifuge, from stuart-equipment, UK. 
 
Mini Shakers, from VWR International, UK. 
 
Osmometer - Osmomat 030, from gonotec, UK. 
 
Oven and Drying Cabinet, from LTE Scientific, UK. 
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Vacuum pump - Welch™ LVS 110 Z Laboratory Vacuum System, from Fisher 
Scientific, UK. 
 
Vortex mixer, from stuart-equipment, UK. 
 
Water bath, Shaking & boiling baths, from Grant Instruments, UK. 
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Consumables 
Aluminium foil, from Merck, UK. 
 
Centrifuge tubes (15 ml), from Sarstedt, Germany. 
 
Coverslips (32 x 32 mm, thickness No.1), from VWR International, UK. 
 
Immersion oil for microscopy, from Sigma-Aldrich, UK. 
 
Microcentrifuge tubes (0.5 ml and 1.5 ml), from Starlab, UK. 
 
Pasteur Pipettes, from Fisher Scientific, UK. 
 
Pipette tips (5 µl, 20 µl, 200 µl, 1 ml and 5 ml), from VWR International, UK. 
 
Polypropylene containers (20 ml, 100 ml and 200 ml), from Starlab, UK. 
 
Surgical Scalpel Blades, from Swann-Morton, UK. 
 
Syringes (0.3 ml, 1 ml and 20 ml) and Needles, from BD, USA. 
 
Weighting boats (46×46×8 mm and 140×140×22 mm), from VWR International, 
UK. 
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Animals 
Wild type (WT) C57BL6/J male mice were purchased from Charles Rivers UK 
Ltd. They were fed standard laboratory chow and water in JBiosi of Cardiff 
University. Generally, mice between 4 and 6 weeks were used for experiments. 
Figure 2.1 shows WT C57BL6/J mouse used in this study. 
 
 
 
Figure 2.1 Wild type mouse. 
The photograph shows a wild type mouse, which is used for pancreatic acinar cell 
isolation. 
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Methods 
 
Preparation of solutions 
The standard buffer solution of Sodium HEPES was practically used for all 
experiments (Table 2.1). This was made up with double distilled water into a 
buffer solution. 
 
Table 2.1 Preparation of NaHEPES buffer (1 L) 
NaCl 140 mM 8.18 g 
KCl 4.7 mM 0.36 g 
HEPES 10 mM 2.4 g 
MgCl2 1 mM 1 ml (from 1 M stock solution) 
Glucose 10 mM 1.8 g 
 
 
Osmolality and pH of the solution was adjusted to 290-300 osm/l and 7.3 by 
the addition of NaCl and NaOH (5 M), respectively. All further solution used the 
standard NaHEPES buffer as a base and 1 mM CaCl2 was added when it was 
necessary. 
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Preparation of collagenase 
18 ml of NaHEPES (supplemented with 1mM CaCl2) buffer was added to 4 KU 
collagenase stock (Figure 2.2) and then mixed well by vortexing to produce a 
222 IU/ml stock collagenase solution. After that, collagenase stock solution 
was divided into 1 ml aliquots in 18 tubes and frozen at -20°C. 
 
 
 
Figure 2.2 Collagenase for pancreatic acinar cell isolation. 
The photograph shows a stock of collagenase, which is used for pancreatic acinar cell 
isolation. 
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Preparation of fluorescent dyes 
Fluo-4-AM  
23 μl of DMSO was added to 50 μg Fluo-4-AM (Figure 2.3) and well mixed by 
vortexing. Then, the stock (2 mM) was aliquoted into 5 μl aliquots in 0.5 ml 
tubes and wrapped with aluminium foil in order to protect from light. All aliquots 
were stored at -20°C. 
 
 
 
Figure 2.3 The chemical structure of Fluo-4. 
Molecular formula: C51H50F2N2O23. Molecular weight: 1096.95. (Modified from Suzuki 
Y & Yokoyama K, Biosensors (Basel), 2015) (298) 
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Fura-2-AM 
25 μl of DMSO was added to 50 μg Fura-2-AM (Figure 2.4) and mixed well by 
vortexing. Then, the stock (2 mM) was aliquoted into 5 μl aliquots in 0.5 ml 
tubes and wrapped with aluminium foil in order to protect from light. All aliquots 
were stored at -20°C. 
 
 
 
Figure 2.4 The chemical structure of Fura-2. 
Molecular formula: C44H47N3O24. Molecular weight: 1001.86. (Modified from Suzuki Y 
& Yokoyama K, Biosensors (Basel), 2015) (298) 
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Rhod-2-AM 
25 μl of DMSO was added to the sample of 50 μg Rhod-2-AM (Figure 2.5) and 
well mixed by vortexing. Then, the stock (2 mM) was aliquoted into 10 μl 
aliquots in 0.5 ml tubes and wrapped with aluminium foil in order to protect 
from light. All aliquots were stored at -20°C. 
 
 
 
Figure 2.5 The chemical structure of Rhod-2. 
Molecular formula: C52H59BrN4O19. Molecular weight: 1123.96. (Modified from Minta A 
et al, J Biol Chem, 1989) (299) 
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TMRM 
25 μl of DMSO was added to the sample of 25 mg TMRM (Figure 2.6) and well 
mixed by vortexing. Then, the stock (10 mM) was aliquoted into 50 μl aliquots 
in 0.5 ml tubes and wrapped with aluminium foil in order to protect from light. 
All aliquots were stored at -20°C. 
 
 
 
Figure 2.6 The chemical structure of TMRM. 
Molecular formula: C25H25N2O3 · ClO4. Molecular weight: 500.93. (Modified from Wang 
B et al, Analyst, 2015) (300) 
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MgGreen 
25 μl of DMSO was added to the sample of 50 μg MgGreen (Figure 2.7) and 
well mixed by vortexing. Then, the stock (2 mM) was aliquoted into 10 μl 
aliquots in 0.5 ml tubes and wrapped with aluminium foil in order to protect 
from light. All aliquots were stored at -20°C. 
 
 
 
Figure 2.7 The chemical structure of MgGreen. 
Molecular formula: C33H17Cl2K5N2O13. Molecular weight: 915.9004. (Modified from 
Suzuki Y & Yokoyama K, Biosensors (Basel), 2015) (298) 
 
 
 
 
 
 
 
 
 
 
72 
 
Preparation of isolated pancreatic acinar cells 
Adult male C57BL6/J mice around 5 weeks old and 20-25g in weight were 
sacrificed by an approved schedule 1 procedure according to the Animal 
Scientific Procedures Act, 1986 and approved by the Ethical Review 
Committee of Cardiff University, that is, mice killed by cervical dislocation. The 
pancreas was excised via a left-sided laparotomy and placed immediately to a 
petri dish containing NaHEPES buffer solution supplemented with 1mM Ca2+. 
The tissue was then washed twice by buffer and removed with excess fat. After 
that, the pancreatic tissue was transferred to an empty weighting boat and 1 ml 
of collagenase (222 IU/ml, worthington) was injected from different angles into 
the tissue. The injected tissue and collagenase was then collected into an 
eppendorf vial sealed with parafilm and incubated in a shaking water bath at 
37°C for 16 – 18 min depending on the actual size of the pancreatic tissue. 
After incubation the tissue was disrupted by repeated manual aspiration with 
dispensing pipette tips of various diameters to produce preparation of single 
pancreatic acinar cell or small acinar clusters. The buffer with cells from the top 
of the eppendorf tube was collected and transferred to a 20 ml centrifuge tube 
and centrifuged for 1 min at 0.2 g-force. The supernatant was discarded and 
the cell pellet was re-suspended in fresh buffer. The cell suspension was spun 
again in order to wash the residual of collagenase and cell debris thoroughly. 
Finally, the cell pellet was re-suspended in NaHEPES buffer solution with 1 
mM Ca2+ and the suspension of pancreatic acinar cells and clusters was ready 
for the fluorescent dye loading procedure. 
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Measurements of [Ca
2+
]i in pancreatic acinar cells 
For measurements of intracellular concentration ([Ca2+]i) in pancreatic acinar 
cells, two Ca2+ sensitive fluorescent probes, namely Fluo-4-AM and Fura-2-AM 
were used. In their esterified form, Fluo-4-AM and Fura-2-AM are uncharged 
and hydrophobic. Therefore, they can easily cross the cell membrane. Once 
the dyes are in the cytosol, acetoxymethyl (AM) esters are removed by cellular 
esterases, which regenerates the free acid forms of fluorescent Fluo-4 and 
Fura-2 and are trapped within the cell and cannot cross the cell membrane. 
 
For measurements of [Ca2+]i with fluorescent probe Fluo-4, pancreatic acinar 
cells were loaded with 5 µM Fluo-4-AM for 30 min at room temperature. Then 
cells were centrifuged for final wash and re-suspended in fresh NaHEPES 
buffer solution containing 1 mM Ca2+. Fluo-4 is well-excited by the 488 nm line 
of the argon-ion laser and its emission wavelength of Ca2+–bound form is the 
506 nm (Figure 2.8) (301). Fluo-4 is a derivative of Fluo-3, however, it is 
brighter and more photostable. Its Ca2+ affinity (Kd ~345 nM) is a slightly higher 
than Fluo-3 (Kd ~390 nM). This makes Fluo-4 brighter at a lower dye 
concentration so that it has shorter incubation times and less phototoxic (302). 
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Figure 2.8 Fluorescence spectra of Fluo-4. 
The graph shows spectra of excitation (blue trace) and emission (red trace) of Fluo-4 
in the presence of Ca2+. (Modified from Gee KR et al, Cell Calcium. 2000) (301) 
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Fura-2 is a ratiometric dye which is one of the most popular calcium indicators 
and has widely been used for quantitative measurement of intracellular [Ca2+]i. 
It is excited by ultraviolet light and its peak absorbance shifts from 380 nm in 
the Ca2+ free state to 340 nm in the Ca2+ bound state (Figure 2.9). In both 
states, the maximum emission intensity is at a wavelength of 510 nm. Fura-2 
has a relative high Ca2+ affinity (Kd ~145 nM) that is similar to endogenous 
resting Ca2+ levels (303). Fura-2 is a dual excitation dye resistant to 
photo-bleaching and the advantage of the ratiometric measurement of [Ca2+]i 
is that it automatically counteracts certain variables such as local differences in 
Fura-2 concentration or cell thickness. However, its main disadvantage is not 
suitable for confocal microscopy. In order to measure [Ca2+]i, freshly isolated 
pancreatic acinar cells were loaded with 2.5 µM Fura-2-AM for 45 min at room 
temperature. The cells were then washed and re-suspended in NaHEPES 
buffer containing 1 mM Ca2+. The [Ca2+]i change were recorded by scientifica 
imaging system with LED excitation 340 nm and 380 nm and the emission 
measured at 510 nm. The ratio signal allows for calculation of intracellular 
[Ca2+]i according to the Grynkiewicz equation (304). 
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Figure 2.9 Fluorescence excitation spectra of Fura-2 at different calcium 
concentrations. 
The graph shows spectra of excitation of Fura-2 in the presence and absence of Ca2+. 
The response at 340 nm is much bigger than 380 nm on binding to Ca2+. (Modified 
from Grynkiewicz G et al, J Biol Chem.1985) (304) 
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Measurements of [Ca
2+
]m in pancreatic acinar cells 
For mitochondrial calcium [Ca2+]m measurements, freshly isolated pancreatic 
acinar cells were loaded with 10 µM Rhod-2-AM for 48 min at 30°C. The AM 
esters of this dye have a net positive charge, which promotes sequestration 
into mitochondria in many cells. Preferentially, Rhod-2 accumulate into the 
mitochondria, however, a substantial fraction of it is also present in the cytosol. 
After incubation the cells were centrifuged for 1 min and re-suspended for a 
final wash and re-suspended in fresh NaHEPES buffer solution containing 1 
mM Ca2+. The fluorescence of Rhod-2 was excited using an argon laser line at 
535 nm, and the emitted light was collected using an LP560 filter. Peak 
excitation and emission wavelengths are 552 nm and 581nm for Rhod-2, 
respectively (Figure 2.10). Unlike Ca2+ sensitive dye Fura-2 and Fluo-4, the 
Ca2+ affinity is relatively low with Kd of ~570 nM for Rhod-2. Generally, the low 
affinity Ca2+ indicators are preferred choices to measure Ca2+ levels in the 
energy generating organelle such as mitochondria. 
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Figure 2.10 Fluorescence spectra of Rhod-2. 
The graph shows spectra of excitation (blue trace) and emission (red trace) of Rhod-2 
in the presence of Ca2+. (Modified from Ronzhina M et al, Physiol Res. 2013) (305) 
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Measurements of Δψm in pancreatic acinar cells 
For Measurements of mitochondrial membrane potential (Δψm) in pancreatic 
acinar cells, the high concentration mode – dequench mode was used for the 
study, which is considered as a considerably more sensitive method of 
evaluation of Δψm that reflects depolarization of mitochondria (306,307). 
Freshly isolated pancreatic cells were loaded with 20 µM TMRM for 25 min at 
room temperature. One potential artifact in employing TMRM for 
measurements of Δψm is that translocation of the charged 
membrane-permeant indicator across the plasma membrane could influence 
the fluorescence (308). Because of the presence of calcium-dependent ionic 
channels in the plasma membrane, the pancreatic acinar cells are able to 
generate rapid changes of membrane potential during calcium responses 
(104). To avoid a possible artifact due to the redistribution of fluorescent dye 
across the plasma membrane, TMRM from the extracellular solution was 
removed prior to experiments, that is, cells were then washed and 
re-suspended in NaHEPES buffer solution containing 1 mM Ca2+. 
Fluorescence was excited by a 535 nm argon laser line, and emission was 
collected above 560 nm. All these experiments were conducted by using a 
Leica TCS SPE confocal microscope with a 63x oil immersion objective. Whole 
cells as the regions of interest were chosen for analyzing the change of 
mitochondrial membrane potential of the dequench mode experiments. This is 
because of both the cytosol and the mitochondrial region responded to 
depolarization of mitochondria with an increase of fluorescence. (308). 
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Measurements of cellular ATP in pancreatic acinar 
cells 
For measurements of intracellular ATP, this was performed with Magnesium 
Green-AM (MgGreen), which senses changes in [Mg2+]i at concentrations 
around the resting [Mg2+]i (approx. 0.9 mM). The cell-permeant Magnesium 
Green-AM exhibits a high affinity for Mg2+ (Kd ~ 1 mM) and the maximum 
fluorescence excitation/emission intensity on binding Mg2+ is ~506/531 nm. As 
most of the intracellular ATP is in the form of Mg-ATP, a reduction of the ATP 
concentration will increase the fluorescence intensity of MgGreen owing to the 
inevitable increase of [Mg2+]i. Therefore, this was used as an indirect approach 
to detect cytosolic ATP depletion (242,309). Pancreatic acinar cells were 
incubated with 4 µM MgGreen for 30 min at room temperature (excitation 488 
nm). ATP depletion mixture (4 µM CCCP, 10 µM oligomycin and 2 mM 
iodoacetate) was applied for a final 10 min to induce maximum ATP depletion 
(310,311).  
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Necrotic cell death assay 
Necrotic cell death assay was assessed by propidium iodide (PI) uptake on 
freshly isolated pancreatic acinar cells as previously described (312,313). PI is 
a popular red-fluorescent nuclear and chromosome counterstain. Since 
propidium iodide is not membrane permeant in viable cells, it is commonly 
used to detect dead cells and assess cell membrane rupture in a population. 
Once the dye is bound to DNA by intercalating between the bases, its 
fluorescence is enhanced 20- to 30-fold. In principle, freshly isolated cells were 
divided into three groups: negative control, positive control and treatment. 
Cells were incubated with various reagents in certain time period interval at 
room temperature and PI were added to every group until the incubation 
finished. Propidium iodide staining of necrotic cells was detected when excited 
by 535 nm laser light and the emission maximum is 617 nm. Multiple images (> 
20) were taken in every group, and the viable and necrotic cells were counted 
afterwards. Generally, every protocol of necrotic cell death assay was 
repeated at least three times and the final data presented as bar chart with 
mean ± SEM. 
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In vivo model of experimental acute pancreatitis 
All animal studies were ethically reviewed and conducted according to UK 
Animals (Scientific Procedures) Act of 1986, approved by the UK Home Office 
(PPL: 30/2956, PIL: I3087FFA9).The animal procedures and experimental 
protocols were approved by Animal Care and Ethics Committees at Cardiff 
school of biosciences, Cardiff University. Before and throughout the 
experiment unless otherwise denoted, mice were maintained in plastic cages 
with corn cob bedding; tap water and commercial pelleted diet were freely 
provided. To establish ASNase-induced AP (ASNase-AP), WT C57BL6/J mice 
received four daily intraperitoneal (IP) injections of Recombinant Asparaginase 
protein (ab73439, Abcam) in phosphate-buffered saline (PBS) at 20 IU/g. 
Control mice only received PBS IP injection. In ASNase-AP model, analgesia 
with 2.5 μg/ml buprenorphine hydrochloride (Temgesic) was orally 
administered. Treatment groups were defined as follows: galactose (180 
mg/kg/day) fed (in drinking water 24 hours before the first ASNase IP injection 
and for the following days during injections) followed by ASNase injection (20 
IU/g) or galactose (180 mg/kg/day) fed with galactose (180 mg/kg/day) 
simultaneously with the first injection of ASNase (20 IU/g; n ≥ 5 mice/group). 
Animals received injections at the same time each day and were sacrificed at 
24 h after the final injection. Body weight was recorded at the first day and the 
day of euthanasia. 
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Histology and score 
Preparation of tissue for light microscopy 
Pancreas and lung tissue samples were fixed in 4% formaldehyde solution for 
24 hours prior to processing. Fixed tissue samples were processed for paraffin 
embedding in Leica TP1050 fully enclosed automatic tissue processor (Figure 
2.11) using the following schedule: 
 
Step Reagent Time 
01 70% Ethanol 1 h 
02 90% Ethanol 1 h 
03 100% Ethanol 1 h 
04 100% Ethanol 1.5 h 
05 100% Ethanol 1.5 h 
06 Xylene 1 h 
07 Xylene 1 h 
08 Paraffin wax 1 h 
09 Paraffin wax 2 h under vacuum 
10 Paraffin wax 2 h under vacuum 
 
After processing the samples were embedded in paraffin wax using a Leica 
EG1150H Embedding Centre (Figure 2.11), the blocks were then placed on a 
Leica EG1140C cold plate to allow the wax to harden rapidly. 
 
Sections were cut at a thickness of 5μm using a Leica RM2235 rotary 
microtome (Figure 2.11), floated on warm water at 45oC and mounted on 
Superfrost plus microscope slides. The sections were dried overnight at 45oC. 
 
Slides were stained with Hematoxylin and eosin (H&E) using an R.A. LAMB 
Histomate staining machine (Figure 2.11) using the following protocol. 
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Step Reagent Time 
01 Xylene 3 min 
02 Xylene 3 min 
03 100% Ethanol 2 min 
04 100% Ethanol 2 min 
05 100% Ethanol 2 min 
06 90% Ethanol 1 min 
07 70% Ethanol 1 min 
08 Running tap water 3 min 
09 Mayer’s Haematoxylin 5 min 
10 Water 5 min 
11 1% Eosin 5 min 
12 Water 30 sec 
13 70% Ethanol 30 sec 
14 90% Ethanol 30 sec 
15 100% Ethanol 1 min 
16 100% Ethanol 2 min 
17 100% Ethanol 2 min 
18 Xylene 1 min 
19 Xylene 2 min 
20 Xylene 2 min 
 
Sections were mounted under a cover glass using DPX mountant. 
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Figure 2.11 Main equipments for tissue preparation. 
A. Tissue processing machine (Leica TP1050).  
B. Embedding Centre (Leica EG1150H). 
C. Rotary microtome (Leica RM2235). 
D. H&E staining machine (R.A. LAMB Histomate). 
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Histological score 
Histological assessment of tissue damage was performed after H&E staining 
of fixed pancreatic slices (4 µm thickness); 15 random fields per slide from all 
animal groups were graded in a blinded manner, without knowledge of the 
experimental design, according to severity and extent of edema, inflammatory 
cell infiltration and acinar necrosis from 0 to 3 by a histopathological grading 
system (Table 2.2) as previously described by Van Laetham et al (314,315). 
 
Table 2.2 Grading criteria used for pancreatic histopathological score. (Modified 
from Wildi S et al, Gut, 2007) (315) 
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Statistical analysis 
Statistical analysis was performed using IBM SPSS Statistics 20.0 software, 
which was issued and technically provided by Cardiff University IT office. Data 
were presented as mean ± SEM. Statistical significance and p-values were 
calculated using t-test or ANOVA, with *p < 0.05 was considered statistically 
significant and **p < 0.01 as highly significant. 
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Chapter 3 
 
Asparaginase-induced pancreatic 
acinar cell death elicited via 
protease-activated receptor 2 
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Overview of protease-activated receptor 2 
Proteinase-activated receptors (PARs) are a novel subfamily of 
seven-transmembrane G-protein-coupled receptors (GPCRs) superfamily in 
mammalian systems (316). Unlike the classic receptor being activated by 
simple ligand occupancy, PARs are uniquely and irreversibly activated 
enzymatically through proteolysis of the N terminus to reveal a tethered ligand 
of the receptor, that is, they are activated by cleavage of part of their 
extracellular domain (316,317). This proteolytic cleavage is specifically 
mediated by the serine proteases resulting in the generation of a new tethered 
ligand that interacts with the receptor within extracellular loop-2 (316,318). 
PARs are expressed predominantly in vascular (highly in platelets), immune 
and epithelial cells, astrocytes and neuron s and transmit cellular responses to 
extracellular proteases expressed in distinct tissues (319–321). There are four 
members of PARs known in mouse and human (322). Human PAR1 (323,324), 
PAR3 (325), and PAR4 (326,327) can be activated by thrombin (328). 
Whereas PAR2 is activated by trypsin (329) and tryptase (330) as well as by 
coagulation factors VIIa and Xa (331,332), but not by thrombin. 
 
It was serendipitous that screening a mouse genomic library by using 
degenerate primers to the second and sixth transmembrane domains of the 
bovine neurokinin 2 receptor resulted in discovery and identification of PAR2 
(329,333). Analysis of the PAR2 N-terminal amino acid sequence revealed a 
putative trypsin cleavage site SKGR34↓S35LIGKV (Figure 3.1) (329,333,334). 
The mechanism by which protease activates PAR2 has been investigated in 
detail. Trypsin cleaves PAR2 at R34↓S35LIGKV to reveal the NH2-terminal 
tethered ligand SLIGKV in humans. This cleavage generates a new tethered 
ligand domain, which binds to conserved regions in the second extracellular 
loop of the cleaved receptor, resulting in the initiation of signal transduction 
(Figure 3.2). Cells derived from tissues e.g. kidney, pancreas, small intestine, 
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colon, and skin are shown to contain abundant mRNA in PAR-2 (334). They 
were also found to respond to trypsin or activating peptide corresponding to 
the tethered ligand domain e.g. SLIGKV (human) and SLIGRL (mouse) without 
the need for receptor cleavage, which furthermore confirmed the presence of a 
functionally and physiologically important receptor (334). Exposure of cells to 
trypsin leads to loss of immunoreactivity to an antibody against an 
NH2-terminal epitope, which proves that trypsin cleaves intact PAR2 at the cell 
surface (335).  
 
PAR2 activation via Gqα rather than Gi (336) generate IP3 and mobilize Ca
2+ in 
PAR2-transfected cell lines, enterocytes, keratinocytes, myocytes, neurons, 
astrocytes and tumor cells (329,334,337–342). PAR2 activation by proteases 
is an irreversible process that exposure of the tethered ligand domain by 
proteases cleavage is always available to interact with the cleaved receptor. 
The principal mechanism that terminates signaling of PARs is that ligand 
occupation of the GPCR induces the translocation of G protein receptor 
kinases (GRKs) from the cytosol to the activated receptor at the cell surface. 
GRKs are serine-threonine kinases that phosphorylate activated GPCR 
through its carboxy terminus or third intracellular loop. Phosphorylation triggers 
the membrane translocation of interaction with β-arrestins to interact with the 
phosphorylated GPCR, which mediate uncoupling of heterotrimeric G proteins 
and desensitization of GPCR, and thereby terminate signal transduction. It 
seems that PKC plays an important role in regulating PAR2 (335,336). 
However, the role of GRKs and β-arrestins in PAR2 desensitization is 
unknown. 
 
PAR2 regulates pancreatic exocrine secretion and its activation stimulates the 
release of amylase from isolated rat pancreatic acini (337) and in vivo rat 
model (343). Furthermore, activation of PAR2 led to increased Ca2+-activated 
Cl- and K+ conductance in pancreatic duct epithelial cells (344). In addition, 
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PAR2 is involved in inflammation and pain (345,346). However, the role of 
PAR2 in acute pancreatitis is still under debate (347–350). 
 
 
Figure 3.1 Structural and functional domains of PAR2. 
The diagram shows alignment of functionally important domains in the amino 
terminus, second extracellular loop, and carboxy terminus of human PAR2. The key 
area of PAR2 receptor activation is highlighted. (Modified from Ossovskaya VS & 
Bunnett NW, Physiol Rev. 2004) (318) 
 
 
 
 
 
 
 
92 
 
 
 
Figure 3.2 Mechanism of protease activation of PAR2. 
Proteolytic cleavage the peptide bond between receptor residues Arg 34 and Ser 35 
leads to the generation of a new tethered ligand designated by the filled section which 
docks intramolecularly with the extracellular loop-2 of the receptor to mediate 
transmembrane signalling. (Modified from Macfarlane SR et al, Pharmacol Rev. 2001) 
(316) 
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The study described in this chapter aimed to investigate the role of 
asparaginase on calcium signaling and evaluate the effects of the drugs CRAC 
channel blocker GSK-7975A and PAR2 antagonist FSLLRY-NH2 on 
asparaginase-induced necrosis in pancreatic acinar cells. 
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Asparaginase increases [Ca
2+
]i in pancreatic acinar 
cells 
As mentioned above, studies on isolated pancreatic acinar cells or cell clusters 
have been showed remarkably helpful to understanding AP. Results in vitro 
have turned out to be excellent predictors of the outcomes of studies in in vivo 
AP models (351–354). Therefore our approach has been to study, for the first 
time, the effects of asparaginase on isolated mouse acinar cells or cell clusters 
are a natural starting point for investigations of the mechanism of AAP. Ca2+ 
has been known for playing the key role in the pathophysiology of AP 
(134,227,228,355,356). Pancreatitis-inducing agents, metabolites of ethanol 
and fatty acids - POAEE (239,242,310) or bile acids (238,354), are able to 
elicit [Ca2+]i elevation in isolated acinar cells causing intracellular Ca
2+ 
overload. This is due to Ca2+ release from internal stores triggering excessive 
store-operated Ca2+ entry (136,312). In order to identify the mechanism of 
action of asparaginase, the effects of asparaginase on [Ca2+]i was initially 
tested over a wide concentration range. Time course is the one of the 
challenges inherent in this approach for a study on normal freshly isolated cells. 
Because AAP typically develops several days after several administrations 
(over many weeks) of asparaginase in the clinical situation (291). However, in 
vitro studies on isolated cells in the laboratory require observations of the 
effects of asparaginase within hours, which is quite different from clinical 
studies.  
 
In the present study, we have tested the effects of different concentration of 
asparaginase on [Ca2+]i and worked with the lowest concentration of 
asparaginase that reliably evoked similar cellular Ca2+ changes associated 
with AP as nonoxdative alcohol metabolites or bile acids did on pancreatic 
acinar cells. To measure [Ca2+]i, pancreatic acinar cells were isolated from 
pancreas of WT mice and loaded with calcium sensitive dye Fluo-4 (see 
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images of the cells in Figure 3.3A). The cells were subsequently exposed to 
asparaginase. We found that a low concentration of asparaginase (20 IU/ml) 
induced [Ca2+]i oscillations only in a few cells (21%, 9 out of 42 cells; Figure 
3.3D). Figure 3.3B shows a representative trace with repetitive Ca2+ spikes 
induced by asparaginase (20 IU/ml), whereas figure 3.3C represents the same 
concentration asparaginase failed to cause any change in [Ca2+]i in majority of 
cells (79%, 33 out of 42 cells; Figure 3.3D). 
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Figure 3.3 Asparaginase induces cytosolic Ca2+ signals in pancreatic acinar 
cells. (Modified from Peng S et al, Philos Trans R Soc Lond B Biol Sci. 2016) (313) 
(A) Images of a doublet of pancreatic acinar cells; transmitted light images (left part) 
and Fluo-4 fluorescence images (right part; scale bar: 10 µm). (B) The representative 
trace shows the low concentration of asparaginase (20 IU/ml) induces repetitive Ca2+ 
spikes in a minority (9 out of 42) of experiments. (C) Asparaginase (20 IU/ml) elicits no 
response in the majority (33 out of 42) of cases. (D) Pie chart shows percentage of 
cells responding to asparaginase (20 IU/ml) with oscillations or not responding at all. 
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A relatively higher concentration of asparaginase (200 IU/ml) was then used to 
test [Ca2+]i in pancreatic acinar cells. The transmitted light picture of a cell 
under investigation is shown in Figure 3.4A1. After exposing the cell to 
Fluo-4-AM, the fluorescence intensity was generally weak, in the absence of 
stimulation, as shown in Figure 3.4A2. However, after a higher concentration of 
asparaginase (200 IU/ml) application, we found that sustained elevated [Ca2+]i 
plateau with top of repetitive [Ca2+]i oscillations was induced in pancreatic 
acinar cells (43 out of 55 cells; Figure 3.4B and C). The development of a 
sustained [Ca2+]i elevation has previously been shown to be a distinctive 
characteristic of [Ca2+]i changes induced by pathological concentrations of 
alcohol metabolites or bile acids. The small elevated [Ca2+]i plateau was seen 
in the vast majority of cells (52 out of 55) stimulated by asparaginase (200 
IU/ml) (Figure 3.4E). In some cases (12 out of 55), there were no, or very few, 
spikes superimposed on the elevated [Ca2+]i plateau (Figure 3.4D). When the 
external solution was changed to Ca2+ free, the sustained [Ca2+]i plateau 
gradually declined to the baseline. Therefore asparaginase (200 
IU/ml)-induced [Ca2+]i elevation depends on the continued presence of Ca
2+ in 
the external solution. 
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Figure 3.4 Asparaginase induces [Ca2+]i changes in pancreatic acinar cells. 
(Modified from Peng S et al, Philos Trans R Soc Lond B Biol Sci. 2016) (313) 
(A) Transmitted light micrograph and Fluo-4 fluorescence images showing the cells 
under investigation (scale bar: 10 µm). (B-D) A higher concentration of asparaginase 
(200 IU/ml) elicits an elevated [Ca2+]i plateau in practically all cases (52 out of 55), 
often with repetitive Ca2+ transients on top of the plateau (43 out of 55) as shown in 
the representative trace B and C. But in some cases (12 out of 55) with no or very few 
spikes as shown in the representative trace D. (E) Pie chart shows percentage of cells 
responding to asparaginase (200 IU/ml) with or without elevated [Ca2+]i plateau. 
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It has previously been shown that the cytosolic Ca2+ overload and ATP 
deprivation induced by fatty acid ethyl esters and bile acids lead to necrosis on 
pancreatic acinar cells, which is the hallmark of AP (136,138). We therefore 
tested if asparaginase also can induce necrosis on pancreatic acinar cells. Cell 
necrotic assays were performed on freshly isolated pancreatic acinar cells by 
propidium iodide (PI) staining. As seen in Figure 3.5, lower concentration of 
asparaginase (20 IU/ml) did not increase the level of necrosis (4.5 ± 0.7% of 
cells) more than the control level (4.6 ± 0.4% of cells, p > 0.8), whereas higher  
concentration of asparaginase (200 IU/ml) significantly induced the level of 
necrosis (15.4 ± 1.8% of cells). Asparaginase kills malignant lymphoblasts by 
depriving them of asparagine through hydrolysis of asparagine (Asn) to 
aspartic acid and ammonia (357). Given that most malignant 
lymphoblasts-unlike normal cells-cannot synthesize Asn by themselves 
(271,358,359). The effects of asparaginase on normal pancreatic acinar cells 
described in this study are therefore unlikely to be owing to Asn deprivation. 
We tested whether there was any difference between the ability of 
asparaginase to induce necrosis in the absence or presence of Asn. As seen in 
Figure 3.5, asparaginase did not significantly increase the level of necrosis 
(14.2 ± 0.8% of cells) in the presence of Asn (50 μM) (360,361) as compared 
with in the absence of Asn (p > 0.6).  
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Figure 3.5 Asparaginase induces necrosis in pancreatic acinar cells, which is 
not dependent on asparagine. (Modified from Peng S et al, Philos Trans R Soc 
Lond B Biol Sci. 2016) (313) 
A lower concentration of asparaginase (20 IU/ml) did not induce any significant 
change in the level of necrosis when compared with control (4.5 ± 0.7% and 4.6 ± 
0.4%, respectively, p > 0.8, each test had four series of experiments with n > 130 of 
tested cells in each group). The presence or absence of asparagine (50 μM) made no 
difference to the level of asparaginase-induced necrosis (p > 0.6, three series of 
experiments with more than 70 cells in each sample). 
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Asparaginase-elicited Ca
2+
 release involves inositol 
1,4,5-trisphosphate receptors 
In order to investigate intracellular Ca2+ release mechanism involved in 
asparaginase-induced [Ca2+]i elevations, caffeine was applied in the study. 
This substance has shown to reliably inhibit IP3R-mediated intracellular Ca
2+ 
release in pancreatic acinar cells (138,352,362,363). As described above, 
pancreatic acinar cells isolated from WT mice and loaded with calcium 
indicator Fluo-4 were used for measuring [Ca2+]i. In the whole series of 
experiments, pancreatic cells were exposed to Ca2+ free external solution. 
Cells were perfused with caffeine (20 mM) for 200 sec incubation and then 
asparaginase (200 IU/ml) was applied to the cells. As shown in Figure 3.6, 
caffeine (20 mM) substantially reduced the asparaginase-induced [Ca2+]i 
elevations in a Ca2+-free solution (p < 0.003; n = 8; compare with Figure 3.8 as 
the appropriate control). Because the asparaginase-elicited Ca2+ release from 
intracellular stores is dependent on functional IP3Rs, we tested whether 
asparaginase acts by stimulating IP3 production. The most widely used 
inhibitor of phospholipase C (PLC) is the aminosteroid compound U73122 
(364,365). Although U73122 is a powerful PLC inhibitor, it has been reported 
that other effects including release of Ca2+ from IP3-sensitive stores 
(364,366,367). We used U73122 at a concentration (10 µM) that abolishes 
cytosolic Ca2+ signal generation evoked by muscarinic receptor activation in 
many systems (364), including pancreatic acinar cells (368). Figure 3.7 shows 
U73122 (10 µM) also significantly blocked the asparaginase-induced Ca2+ 
release as well as the response to 1 µM ACh (p < 0.001; n = 11). Figure 3.9 
compares Ca2+ responses in a form of a bar chart. Areas under the traces of 
application of asparaginase within 10 min from Figure 3.6, 3.7 and 3.8 were 
calculated. Both caffeine and U73122 markedly inhibited 
asparaginase-induced Ca2+ signals in pancreatic acinar cells. 
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Figure 3.6 Caffeine inhibits asparaginase-induced cytosolic Ca2+ responses. 
(Modified from Peng S et al, Philos Trans R Soc Lond B Biol Sci. 2016) (313) 
The representative trace shows the IP3R blocker caffeine (20 mM) substantially 
reduced the asparaginase-induced [Ca2+]i elevations in the absence of external Ca
2+ 
in pancreatic acinar cells (n = 8).  
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Figure 3.7 U73122 blocks asparaginase-induced cytosolic Ca2+ responses. 
(Modified from Peng S et al, Philos Trans R Soc Lond B Biol Sci. 2016) (313) 
The representative trace shows the PLC inhibitor U73122 (10 µM) blocked the 
asparaginase-induced [Ca2+]i elevation in the absence of external Ca
2+ in pancreatic 
acinar cells (n = 11). 
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Figure 3.8 Cytosolic Ca2+ responses to asparaginase in Ca2+ free solution. 
(Modified from Peng S et al, Philos Trans R Soc Lond B Biol Sci. 2016) (313) 
The representative trace shows asparaginase (200 IU/ml) induces Ca2+ oscillations in 
the absence of external Ca2+ in pancreatic acinar cells (n = 9). 
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Figure 3.9 Pre-incubation of Caffeine or U73122 substantially reduced 
asparaginase-induced cytosolic Ca2+ responses. (Modified from Peng S et al, 
Philos Trans R Soc Lond B Biol Sci. 2016) (313) 
The bar chart shows average area under the traces depicted in Figure 3.6, 3.7 and 
3.8 of the recorded responses during the first 500 s of asparaginase application. Data 
represent mean ± SEM. IP3R blocker caffeine (20 mM) and PLC inhibitor U73122 (10 
µM) significantly blocked the asparaginase-induced [Ca2+]i elevation in the absence of 
external Ca2+ in pancreatic acinar cells (p < 0.003).  
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The asparaginase-elicited sustained increase in [Ca
2+
]i 
depends on the presence of external Ca
2+
 
It is clearly that Ca2+ entry plays an important role in the formation of the 
sustained elevated [Ca2+]i plateau in pancreatic acinar cells (136,227). As we 
observed in the previous experiments, removal of external Ca2+ always 
terminated the elevated [Ca2+]i plateau (Figure 3.4B,C,D). In order to assess 
extracellular Ca2+ contributing to the asparaginase-induced elevated [Ca2+]i 
plateau, different protocols were designed to further characterise 
asparaginase-elicited [Ca2+]i elevation by Ca
2+ entry. We firstly tried simply 
removal of external Ca2+ and stimulating pancreatic acinar cells with 
asparaginase (200 IU/ml), and we found that cells only developed repetitive 
Ca2+ spikes without generation of sustained elevated [Ca2+]i plateau (n = 28, 
Figure 3.10).  
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Figure 3.10 The effect of removal of external Ca2+ abrogates 
asparaginase-induced elevated [Ca2+]i plateau. (Modified from Peng S et al, Philos 
Trans R Soc Lond B Biol Sci. 2016) (313) 
Representative trace shows asparaginase induces repetitive Ca2+ transients in Ca2+ 
free solution without sustained [Ca2+]i plateau (n = 28).  
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Another way to demonstrate asparaginase-elicited [Ca2+]i elevation is 
dependent on external Ca2+ was to investigate the effect of a Ca2+ chelator 
EGTA (128) on asparaginase-elicited [Ca2+]i change. Freshly isolated 
pancreatic acinar cells loaded with Fluo-4 were exposed to asparaginase (200 
IU/ml) in the absence of external Ca2+ and then increasing the extracellular 
Ca2+ concentration to 2 mM during asparaginase stimulation. This caused a 
marked and sustained increase in [Ca2+]i (n = 18, Figure 3.11). Subsequent 
extracellular solution was changed to Ca2+ free buffer containing the Ca2+ 
chelator EGTA (200 µM). As shown in Figure 3.11, elevated [Ca2+]i plateau was 
rapidly decreased and abolished finally, whereas the Ca2+ oscillations 
continued for some time. Finally, pharmacological inhibition was performed by 
using selective CRAC channel blockers GSK-7975A (369,370). It has 
previously been proved that GSK-7975A can markedly inhibit excessive Ca2+ 
entry into pancreatic acinar cells induced by alcohol metabolites or bile acids 
and prevent their pathological effects on pancreatic acinar cells (312,354,371). 
We have therefore tested the effect of CRAC blockade on the 
asparaginase-induced sustained [Ca2+]i elevation. Freshly isolated pancreatic 
acinar cells were preincubated with GSK-7975A (10 µM) for 10 min, and then 
asparaginase was applied to the cells. Figure 3.12 shows GSK-7975A 
abolished the elevated [Ca2+]i plateau, although repetitive Ca
2+ spiking was still 
observable within the time frame of the experiments (n = 32). Figure 3.13 
summarizes the degree of inhibition, caused by removal of external Ca2+ or by 
GSK-7975A, of the integrated Ca2+ signal evoked by asparaginase. 
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Figure 3.11 Increasing external calcium dramatically increases calcium plateau 
while calcium removal blocks asparaginase-induced elevated [Ca2+]i plateau. 
(Modified from Peng S et al, Philos Trans R Soc Lond B Biol Sci. 2016) (313) 
Representative trace shows when the external Ca2+ concentration is increased from 1 
to 2 mM, there is a marked transient [Ca2+]i rise and a continuing elevated [Ca
2+]i 
plateau. When subsequently removal of external Ca2+ and addition of the Ca2+ 
chelator (EGTA), the plateau gradually disappears (n = 18).  
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Figure 3.12 The effect of CRAC blockade on the asparaginase-induced elevated 
[Ca2+]i plateau. (Modified from Peng S et al, Philos Trans R Soc Lond B Biol Sci. 2016) 
(313) 
The typical trace shows in the presence of the CRAC channel blocker GSK-7975A (10 
µM), asparaginase (200 IU/ml) evokes repetitive Ca2+ spikes without an elevated 
[Ca2+]i plateau (n = 32). 
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Figure 3.13 Comparison of asparaginase-elicited [Ca2+]i response among 
presence or absence of external Ca2+ or CRAC blockade. (Modified from Peng S 
et al, Philos Trans R Soc Lond B Biol Sci. 2016) (313) 
Comparison of the integrated Ca2+ signals (‘area under the curve’ from start of the 
Ca2+ signal until 30 min later), the bar chart shows that in the absence of external Ca2+ 
(n = 28) or in the presence of 1 mM external Ca2+ with the addition of the CRAC 
blocker GSK-7975A (n = 32) significantly (p < 0.0001 in both cases) reduced the 
responses to asparaginase (200 IU/ml) as compared to control in the presence of 
1mM Ca2+ (n = 55; Figure 3.4). Bars represent mean ± SEM. 
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It is clear that excessive store-operated Ca2+ entry via CRAC channels is 
crucial for pathological Ca2+ signalling generation in pancreatic acinar cells, 
which leads to cell death (136,194,240,372). In the recent studies of 
store-operated Ca2+ influx, it has been shown that inhibition of Ca2+ entry into 
pancreatic acinar cells induced by non-oxidative product of combination of 
alcohol and fatty acids (fatty acid ethyl ester, FAEE), or bile acids could 
effectively protect against their pathological effects by the CRAC channel 
blocker GSK-7975A (312,354). We have therefore decided to check the effect 
of inhibition of Ca2+ entry channels by CRAC blocker (GSK-7975A, 10 μM) on 
the asparaginase- induced necrotic cell death pathway activation. Figure 3.14A 
shows representative images of some of the cells under the treatment 
protocols, together with the results of staining for PI. It is seen that 
asparaginase (200 IU/ml) elicited strong intracellular PI staining and that 
GSK-7975A provided protection against this. Pre-incubation of the CRAC 
channel inhibitor GSK-7975A (10 µM) (312,354) dramatically reduced the level 
of asparaginase-induced necrosis (5.8 ± 0.8% of cells) near to the control level 
(4.6 ± 0.8% of cells) (Figure 3.14B). 
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Figure 3.14 Inhibition of CRAC channels by GSK-7975A dramatically reduces 
asparaginase-induced necrosis. (Modified from Peng S et al, Philos Trans R Soc 
Lond B Biol Sci. 2016) (313) 
(A) Representative transmitted light images (upper row) and PI-stained fluorescence 
images (lower row; scale bar: 10 µm) of cells from the experiments shown in Figure 
3.14B. (B) The CRAC channel inhibitor GSK-7975A (10 μM) essentially abolished 
asparaginase-induced necrosis to a level not significantly different from control (p > 
0.3), while significantly (p < 0.0001, eight series, n > 70) lower than that caused by 
asparaginase (200 IU/ml) alone (17.8 ± 1.2% of cells). 
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Asparaginase-induced pathology depends on 
protease-activated receptor 2 
As mentioned above, PAR2 is widely expressed in human and animal tissues, 
including the pancreas, lung, kidney, stomach, liver, colon, small intestine and 
immune and endothelial cells (329,337,373,374). PAR2 has previously been 
implicated in pain and inflammation (345,346) and contributions to 
gastrointestinal regulation in health and disease (375,376), including the 
pathology of AP (348–350). The activation of PAR family members is coupled 
to multiple heteromeric G proteins that lead to PLC activation and production 
of IP3 and diacylglycerol, which can cause Ca
2+ mobilization (317). Since the 
effect of asparaginase on Ca2+ signalling has been observed, we therefore 
tested the possibility that asparaginase could activate PAR2. Figure 3.15A,B 
shows the different concentrations (10 nM, 100 nM, 200 nM or 500 nM) of the 
potent PAR2 agonist AC-264613 (377) induced Ca2+ oscillations in pancreatic 
acinar cells. We then investigated the effect of the PAR2 blocker FSLLRY-NH2 
(378–381) on asparaginase-elicited [Ca2+]i changes. As seen in Figure 3.16A, 
pre-incubation of FSLLRY-NH2 (10 µM; n = 32) for 200 s before the addition of 
asparaginase significantly reduced the asparaginase-induced the sustained 
[Ca2+]i elevation as well as [Ca
2+]i oscillations (n = 30, Figure 3.16B). Figure 
3.16C and D show the mean values of all of the data from Figure3.16A and B. 
It is clear that PAR2 antagonist FSLLRY-NH2 very markedly inhibits the [Ca
2+]i 
elevation (p < 0.0001) and oscillations (p < 0.001) normally evoked by 200 
IU/ml asparaginase. Due to the effect of FSLLRY-NH2 markedly inhibits 
sustained global [Ca2+]i elevation evoked by asparaginase, thereby, we tested 
FSLLRY-NH2 on necrotic death assay and we found that the PAR2 inhibitor 
FSLLRY-NH2 (10 µM) significantly reduced the level of asparaginase-induced 
necrosis (6 ± 0.5% of cells) close to the control level (3.3 ± 0.2% of cells, p < 
0.0001; Figure 3.16E). 
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Figure 3.15 PAR2 agonist AC-264613-elicited [Ca2+]i response. (Modified from 
Peng S et al, Philos Trans R Soc Lond B Biol Sci. 2016) (313) 
(A) Representative trace shows AC-264613 (10 nM, 100 nM or 200 nM) induces 
[Ca2+]i changes (n = 6). (B) AC-264613 (500 nM) elicits repetitive Ca
2+ spike (n = 4). 
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Figure 3.16 PAR2 antagonist FSLLRY-NH2 significantly inhibited 
asparaginase-induced Ca2+ signals and necrosis. (Modified from Peng S et al, 
Philos Trans R Soc Lond B Biol Sci. 2016) (313) 
The representative trace shows the asparaginase-induced Ca2+ signals (n = 30; 
Figure 3.16B) were eliminated by the PAR2 inhibitor FSLLRY-NH2 (10 µM, n = 32; 
Figure 3.16A). (C) The bar chart shows average area under the traces depicted in 
Figure 3.16A and B between 200 s and 2000 s of the recorded responses. (p < 
0.0001). (D) The bar chart shows FSLLRY-NH2 reduces repetitive Ca
2+ spike evoked 
by asparaginase (p < 0.001). Data presented as mean ± SEM. (E) The PAR2 inhibitor 
FSLLRY-NH2 (10 μM) significantly blocked the asparaginase-induced necrosis (p < 
0.0001; four series of experiments with n > 150 cells in each sample). 
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We tested whether asparaginase-elicited [Ca2+]i response via muscarinic 
receptor (50,53). Pancreatic acinar cells were stimulated by ACh (50 nM) and 
then washed by NaHepes buffer. After that atropine (1 µM) (382–384) was 
applied to the acinar cells and incubated for 100 s and then re-exposed to ACh 
(50 nM). Atropine is the competitive nonselective antagonist at central and 
peripheral muscarinic acetylcholine receptors (385). There was not Ca2+ 
spikes developed after atropine application, which shows completely blockade 
of muscarinic receptors. Additional of asparaginase (200 IU/ml) after ACh 
washed out again, as shown in Figure 3.17A, evoked sustained [Ca2+]i 
elevation response with Ca
2+ oscillations (n = 22). Finally, CCK (50 pM) was 
applied into the acinar cells, which caused Ca2+ spike. Comparison of area 
under the response of asparaginase (n = 30, Figure 3.16B), inhibition of 
muscarinic receptors by atropine does not change asparaginase-induced 
[Ca2+]i changes (Figure 3.17B; p > 0.15). 
 
We also tested the effect of PAR2 antagonist FSLLRY-NH2 on muscarinic 
receptor and we found that pre-incubation of FSLLRY-NH2 (n = 36, Figure 
3.18B) did not affect physiological concentration of ACh (50 nM)-induced 
[Ca2+]i signals (n = 18, Figure 3.18A) in pancreatic acinar cells (Figure 3.18C; 
p > 0.2). 
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Figure 3.17 Asparaginase-induced Ca2+ signals do not depend on muscarinic 
receptor.  
Nonselective muscarinic acetylcholine receptors antagonist atropine does not block 
asparaginase-induced [Ca2+]i response (A; n = 22). The bar chart (C) shows 
comparison of the integrated Ca2+ signals elevation above the baseline (area under 
the curve) shown in A and Figure 3.16B (n = 30) recorded during the 30 min of 
asparaginase application. The mean values (± SEM) are not significantly different (p > 
0.15). 
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Figure 3.18 PAR2 antagonist FSLLRY-NH2 does not affect ACh-induced Ca
2+ 
signals.  
(A) Typical trace shows ACh-induced Ca2+ signalling in pancreatic acinar cell (n = 18). 
(B) Pre-incubation of PAR2 antagonist FSLLRY-NH2 does not block ACh-induced Ca
2+ 
oscillations (n = 36). (C) The bar chart shows comparison of the integrated Ca2+ 
signals elevation above the baseline (area under the curve) shown in Figure A and B 
recorded during the 5 min of ACh application (p > 0.2). Data presented as mean ± 
SEM. 
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Ca
2+
 entry and extrusion mechanisms are affected by 
asparaginase 
To study Ca2+ movements in more detail, a specific protocol routinely used to 
assess Ca2+ entry and extrusion have been applied. Our standard protocol for 
store-operated Ca2+ entry investigations consisted of first emptying the ER 
store of Ca2+ by applying the specific ER Ca2+ pump blocker cyclopiazonic acid 
(CPA) in a nominally Ca2+-free solution. This caused a transient rise in [Ca2+]i 
(Figure 3.19A). After [Ca2+]i had returned to near its normal resting level, Ca
2+ 
(2 mM) was added to the external solution for a short period and then removed. 
Additional of external Ca2+ resulted in a substantial rise in [Ca2+]i, which was 
sustained as long as Ca2+ was present outside the cell. In the presence of 
asparaginase (200 IU/ml), the Ca2+ entry following external Ca2+ admission 
was significantly increased (Figure 3.19A), assessed by both amplitude of the 
[Ca2+]i change (Figure 3.19B) and the rate of [Ca
2+]i increase (half-time of the 
decrease, Figure 3.19C). However, the most obvious change seen in Figure 
3.19A is quantitatively the most important effect of asparaginase which was to 
attenuate Ca2+ signals after removal of external Ca2+. The half-time of [Ca2+]i 
recovery of the cells treated with asparaginase (200 IU/ml) was more than 
three times longer than in the control cells (Figure 3.19D). 
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Figure 3.19 Asparaginase accelerates Ca2+ entry and substantially slows down 
Ca2+ extrusion. (Modified from Peng S et al, Philos Trans R Soc Lond B Biol Sci. 
2016) (313) 
(A) In the absence of external Ca2+, CPA, a specific inhibitor of the Ca2+ pump in the 
ER membrane, causes a modest and largely transient [Ca2+]i rise. When subsequently 
2 mM Ca2+ is added to the external solution, there is a marked rise in [Ca2+]i, which 
then declines after removal of external Ca2+. In the presence of asparaginase (red 
averaged trace, n = 32), the amplitude (B) and the rate of rise of [Ca2+]i (C) are 
somewhat increased (p < 0.05 and p < 0.0001, respectively) when compared with 
control (A, blue averaged trace, n = 34). The extrusion of Ca2+ by the plasma 
membrane Ca2+ pumps, observed as the decline in [Ca2+]i following removal of 
external Ca2+, is very markedly and significantly (p < 0.0001) reduced in the presence 
of asparaginase (A,D). 
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Discussion 
The findings presented in this chapter provide the first mechanistic insights into 
the process by which asparaginase treatment of ALL may cause acute 
pancreatitis. These insights also provide the first pointers to rational therapies 
that may prevent the currently necessary cessation of asparaginase treatment 
in cases of severe pancreatitis. Our data indicate that the 
asparaginase-induced pathological effects have much in common with those 
elicited by the ‘classical’ pancreatitis-inducing agents such as alcohol and fatty 
acids and, particularly, combinations of alcohol and fatty acids as well as bile 
acids (236,386,387). Ca2+ overloading, due to excessive intracellular Ca2+ 
release followed by excessive Ca2+ entry are central in all cases. 
 
CRAC channels seem to be the most accessible therapeutic target for AAP 
(312,354,371,372,388). We have now shown that the asparaginase-induced 
Ca2+ elevations depend on CRAC-mediated Ca2+ entry and, therefore, are 
strongly inhibited by the CRAC channel inhibitor GSK-7975A (Figure 3.12 and 
13). Consequently, asparaginase-induced necrosis can also be dramatically 
reduced to near control levels by GSK-7975A (Figure 3.14). Given the 
previously documented protective effects of Ca2+ entry channel inhibition 
against alcohol-related pancreatic pathology in isolated cell clusters, which  
including pancreatic acinar cells and stellate cells (389,390), and the more 
recent confirmation of its effectiveness in vivo in three different mouse 
pancreatitis models (354), our new data suggest very strongly that this 
therapeutic approach should also be successful against asparaginase-induced 
pancreatitis.  
 
Interestingly, the asparaginase-induced pathological effects do not depend on 
the presence of the substrate of the enzyme, namely asparagine (Figure 3.5). 
Asparaginase induces [Ca2+]i elevations, and thereby its pathological effects, 
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through protease activated receptor 2 (PAR2) rather than muscarinic receptor 
(Figure 3.17). PAR2 has previously been implicated in acute pancreatitis, 
although its exact role is still debatable (347–350). Blocking PAR2 in our 
experiments inhibited both the pathological [Ca2+]i elevations and the 
asparaginase-induced necrosis (Figure 3.16), suggesting that PAR2 inhibitors 
in addition to, or in combination with, CRAC channel inhibitors (312,354,372) 
and calmodulin activators (119,391) could be a useful tool to supplement 
asparaginase ALL treatment in AAP cases.  
 
Both Ca2+ entry and extrusion are significantly affected by asparaginase, 
leading to formation of the pathological elevated [Ca2+]i plateau and this 
sustained elevation of [Ca2+]i is somehow responsible for the necrosis. The 
demonstrated reduction of the intensity of Ca2+ extrusion (Figure 3.19) is 
clearly a key element and the simplest postulation and explanation for this is 
the reduction in the intracellular ATP level limiting the energy supply to the 
Ca2+ ATPase in the plasma membrane. In order to investigate this point, 
further experiments were undertaken using fluorescent probers for 
mitochondrial activity and ATP dynamics by confocal microscopy and these 
are described in next chapter. 
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Chapter 4 
 
Asparaginase affects mitochondrial 
function and glucose metabolism in 
pancreatic acinar cells 
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Overview of mitochondrial functions 
It has been universally acknowledged that mitochondria are important for 
cellular functions (392). The complex transport pathways play an essential role 
in mitochondrial function as well as cell physiology (393). Many digestive 
proenzymes are synthesized in the pancreatic acinar cells. These inactive 
enzymes are packaged into secretory (zymogen) granules and secreted by 
exocytosis upon the action of the neurotransmitter ACh (52,394) or the 
circulation hormone CCK (395). These secretagogues mobilize Ca2+ from 
internal stores and thus generate the physiological Ca2+ signalling that 
regulate exocytosis, which requires Ca2+, Mg2+ and ATP (182,396). Therefore, 
Ca2+ homeostasis and energy demand made the functions of pancreatic acinar 
cells are highly dependent on the mitochondria. As a consequence, the 
pancreatic acinar cells have evolved in such a way that the mitochondria are 
distributed in very specific positions in the cells and play different roles at these 
different sites. Functionally, there are three distinct sets of mitochondria in 
pancreatic acinar cells (Figure 4.1) (71,109). The highest density of 
mitochondria was found on the border between the granular and baso-lateral 
regions. This so called mitochondrial belt is often referred to as the 
peri-granular mitochondria. The second group, called peripheral or 
sub-plasmalemmal, is located very close to the basolateral plasma membrane. 
Another set surrounds the nucleus, and these mitochondria are therefore 
named as perinuclear.  
 
As mentioned above, mitochondria are mainly situated on the border between 
the apical granular region and the baso-lateral part of the cells (71). This 
special arrangement implicates a significant physiological role in pancreatic 
acinar cells. Since it was already known that physiological Ca2+ signals were 
initiated in the apical pole and mostly confined to the granular region 
(50,52,397), it seemed likely that the peri-granular mitochondrial belt could 
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confine physiological Ca2+ signals to the apical region as a Ca2+ buffer barrier.  
This hypothesis was demonstrated by Tinel et al (71). They observed that the 
IP3-indcued physiological Ca
2+ signal pattern consisting of repetitive local Ca2+ 
spikes was transformed into a global sustained [Ca2+]i elevation by application 
of the ionophore CCCP, which indicated that Ca2+ released from the ER in the 
apical granular pole is rapidly taken into the peri-granular mitochondria and 
only released very slowly. Therefore, mitochondria belt by means of buffering 
Ca2+ to prevent the cytosolic Ca2+ wave spreading from apical granular pole 
into the basal region. The mitochondrial Ca2+ uniporter (MCU) (187) is mainly 
responsible for soaking up Ca2+ released from the ER and the Na+/Ca2+ 
exchangers (398) extrude Ca2+ slowly from mitochondrial to the cytosol (399). 
Hence, this specific function of mitochondria on regulating Ca2+ signals in 
pancreatic acinar cells that enable the peri-granular mitochondrial belt to buffer 
Ca2+ and thereby confining the cytosolic Ca2+ spikes to the apical granular 
area (Figure 4.2). 
 
The peripheral (sub-plasmalemmal) mitochondria are distributed just below the 
basolateral plasma membrane (Figure 4.1). Ca2+ uptake specifically into 
peripheral mitochondria during store-operated Ca2+ entry is essential for the 
function of peripheral mitochondria, that is, Ca2+ entry across the basal 
membrane lead to local mitochondrial Ca2+ uptake stimulating local ATP 
production (Figure 4.2). It is not clear that a major part of the store-operated 
Ca2+ entry is directed into the mitochondria or whether most of it goes directly 
into the ER. However, it has been shown that Ca2+ influx into the acinar cells 
through store-operated calcium channels (SOCs) in the basal membrane is 
immediately taken up into the ER by Ca2+ pumps (66). Moreover, electron 
microscopical images of the region just below the baso-lateral plasma 
membrane show ER is in closer contact with the surface membrane than the 
mitochondria (147). This indicates the most likely Ca2+ entry points and 
supports the point of view that Ca2+ is immediately taken up into the ER during 
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store-operated calcium entry. Nevertheless, Ca2+ uptake into the peripheral 
mitochondria are functionally important for ATP generation which is needed 
locally to fuel the ER Ca2+ pumps (Figure 4.2). There are also increasing 
evidences indicating that store-operated Ca2+ entry depends on the 
mitochondrial function (400–402).  
 
The perinuclear mitochondria (Figure 4.1) have a lower density than the 
peri-granular mitochondria or peripheral mitochondria. The function of the 
perinuclear mitochondria is most likely to serve as a protection barrier for the 
nucleus in pancreatic acinar cells (Figure 4.2). In this scenario, exocytotic 
secretion-coupled Ca2+ signalling does not necessarily have to enter the 
nucleus. This is important because the nuclear pore complexes scarcely resist 
to Ca2+ flow (403,404). Although the function of perinuclear mitochondria 
remains elusive, it cannot be denied that the perinuclear mitochondria are 
helpful and effectively a special Ca2+ microdomain generation in the nucleus 
as a Ca2+ buffer barrier (109,405). 
 
This chapter is aim to explore the effects of asparaginase on mitochondrial 
function and determine potential ways to intervene asparaginase-associated 
ATP depletion and mitochondrial Ca2+ overload in pancreatic acinar cells. 
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Figure 4.1 Distribution of mitochondria in pancreatic acinar cells. 
Typical confocal images show a transmitted light micrograph (A) and a fluorescence 
image (B; mitotracker green), respectively, illustrating the distribution of all the 
mitochondria in an isolated triplet of pancreatic acinar cells [PG-M: peri-granular 
mitochondria; SP-M: sub-plasmalemmal (peripheral) mitochondria (very weakly 
represented in this image); PN-M: perinuclear mitochondria]. Scale bar is 10 μm. 
(Modified from Johnson PR et al, Cell Tissue Res. 2003) (181) 
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Figure 4.2 The location and function of three different groups of mitochondria in 
pancreatic acinar cell. 
Schematic image illustrate three distinct sets of mitochondria in pancreatic acinar 
cells: the peri-granular mitochondria, the peripheral (sub-plasmalemmal) mitochondria 
and the perinuclear mitochondria. For the details of Ca2+ transport and ATP supply 
see the full description in text. (Adapted from Park MK et al, EMBO J. 2001) (109) 
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Asparaginase depletes intracellular adenosine 
triphosphate in pancreatic acinar cell 
Ca2+ extrusion is an energy-demanding process, in which PMCA removes Ca2+ 
by the hydrolysis of adenosine triphosphate (ATP) (406). It has previously 
been found that Ca2+ extrusion was abnormal in pancreatic acinar cell 
pathologies as a result of disruption of mitochondrial metabolism and, 
therefore, reduction of ATP levels (311,407,408). To assess intracellular ATP 
concentration changes in pancreatic acinar cells, indirect measurements by 
using Magnesium Green (MgGreen) fluorescence (Figure 4.3A) was 
conducted in our study. Because both ATP and Mg2+ are mutually and strongly 
buffered in the cytosol, most of the intracellular ATP forms biologically 
functional unit as Mg-ATP complexes to compose (409). Hence, a reduction of 
the ATP concentration will increase the fluorescence intensity of MgGreen 
owing to the inevitable increase of [Mg2+]i (242,410,411). Using the MgGreen 
technique, asparaginase (200 IU/ml) induced a substantial reduction of 
intracellular ATP levels superseded only by the full ATP depletion caused by a 
mixture of the protonophore CCCP, oligomycin and iodoacetate (n = 39; Figure 
4.3B) (311) . Because Ca2+ entry was contributed to Ca2+ overload and the 
cytoplasmic and mitochondrial effects induced by asparaginase, we therefore 
tested if inhibition of Ca2+ entry channels (312,354,371) could affect the ATP 
loss evoked by asparaginase. Blocking Ca2+ entry by GSK-7975A (10 μM) 
markedly reduced the asparaginase-induced ATP depletion (n = 21, p < 0.0001; 
Figure 4.3C and E). It has been previously reported that ethyl pyruvate, 
aliphatic ester derived from pyruvic acid (412), had protective effect in the in 
vivo biliary pancreatitis mode and attenuated the severe AP induced by 
sodium taurocholate in rats (413–415). We next wanted to investigate whether 
this was due to preservation of ATP, and therefore tested the effect of pyruvate 
on asparaginase-induced ATP loss. Additional of pyruvate (1 mM) in the 
external solution resulted in the asparaginase-induced ATP loss substantially 
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reduced as compared with control experiments (n = 8, p < 0.0001; Figure 4.3D 
and E). 
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Figure 4.3 Asparaginase reduces intracellular ATP levels as assessed by 
increases in [Mg2+]i. (Modified from Peng S et al, Philos Trans R Soc Lond B Biol Sci. 
2016) (313) 
Confocal images of a cluster of pancreatic acinar cells; the left part represents the 
confocal image of MgGreen fluorescence, and the right part shows the transmitted 
image of the cells (Figure 4.3A; scale bar: 10 µm). Asparaginase (200 IU/ml) markedly 
increased [Mg2+]i and a further rise occurred after poisoning mitochondrial function 
with a cocktail of CCCP (4 μM), oligomycin (10 μM) and sodium iodoacetate (2 mM) (n 
= 39; Figure 4.3B). Average traces show the relative MgGreen fluorescence (F/F0) in 
response to Asparaginase (200 IU/ml) followed by the “ATP depletion” mixture in 
GSK-7975A-treated cells (n = 21; Figure 4.3C) and pyruvate-treated cells (n = 8; 
Figure 4.3D). Comparisons of the integrated responses (‘areas under the curve’ from 
the start of the responses until 1800 s later) show that GSK-7975A or pyruvate 
significantly reduced the asparaginase-induced ATP depletion (p < 0.0001 for both 
treatments). 
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Asparaginase affects mitochondrial membrane 
potential in pancreatic acinar cell 
In the previous chapter (Chapter 3), we have demonstrated that asparaginase 
dramatically slowing down Ca2+ extrusion in pancreatic acinar cells (Figure 
3.19). Since Ca2+ extrusion in pancreatic acinar cell is the ATP dependent 
process, we decided to investigate more details of asparaginase acting on 
mitochondria. The high concentration mode of TMRM (dequench mode) 
measurements is highly sensitive reflecting the changes in mitochondrial 
membrane potential (Δψm) (308) and therefore dequench mode was applied in 
our experiments. 
 
Figure 4.4A shows a typical dequench mode of high concentration of TMRM 
(10 μM) loading in pancreatic acinar cells. Application of asparaginase (200 
IU/ml) resulted in increases of fluorescence in cells (n = 33; Figure 4.4B). The 
subsequent addition of 5 nM CCCP resulted in fast and large further increases 
of fluorescence in all cells.  
 
Since the protective effect of pyruvate in asparaginase-induced pancreatic 
acinar cell necrosis was observed, we therefore applied pyruvate in the 
dequench mode. As seen in Figure 4.4C, pre-incubation of pyruvate (1 mM) 
markedly abolished the fluorescence intensity increasing induced by 
asparaginase (n = 12, p < 0.01).  
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Figure 4.4 Asparaginase induces mitochondrial depolarization. 
(A) Confocal images of a cluster of pancreatic acinar cells; the left part represents the 
confocal image of TMRM distribution, and the right part shows the transmitted image 
of the cells (scale bar: 10 µm). (B) Responses of the mitochondrial membrane 
potential probe TMRM to asparaginase. The average traces show effects of 
asparaginase followed by CCCP on mitochondrial membrane potential to pancreatic 
acinar cells loaded with 10 µM TMRM (dequench mode, n = 33). (C) The average 
traces show protective effects of ATP supplementation with 1mM pyruvate (n = 16) on 
asparaginase-induced change of mitochondrial membrane potential. (D) 
Comparisons of the integrated responses (‘areas under the curve’ from the start of the 
responses of application of asparaginase) show that pyruvate significantly reduced 
the asparaginase-induced change of mitochondrial membrane potential. (p < 0.05). 
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Asparaginase affects mitochondrial calcium in 
pancreatic acinar cell 
Mitochondrial Ca2+ plays an essential role in regulating mitochondrial 
metabolism (184) and has a direct role in driving ATP production (416). Since 
the effect of asparaginase-induced mitochondria depolarization and ATP 
depletion have been observed above, here we have investigated how 
mitochondrial Ca2+ concentration ([Ca2+]m) affect the response to asparaginase 
by pancreatic acinar cells. To image mitochondria and measure [Ca2+]m in 
freshly isolated pancreatic acinar cells, Ca2+ dye Rhod-2 (299,417) was 
applied in the experiments, for this dye is concentrated in cellular 
compartments with a high negative voltage. As shown in Figure 4.5A, the 
polarized doublet pancreatic acinar cells has the strongest staining located as 
a ring surrounding in granular area with some staining in periphery. It has been 
demonstrated that ER-derived [Ca2+]i increase results in mitochondrial Ca
2+ 
uptake immediately (418). After Rhod-2 loaded cells exposed to asparaginase 
(200 IU/ml), we found that [Ca2+]m immediately increase and gradually reach to 
the sustained plateau (n = 14; Figure 4.5B). When ACh (1 μM) was applied to 
the cells, there was no more [Ca2+]m response to be elicited. 
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Figure 4.5 Asparaginase induces [Ca2+]m elevation in pancreatic acinar cells. 
(A) Confocal images of a cluster of pancreatic acinar cells; the left part represents the 
confocal image of Rhod-2 fluorescence, and the right part shows the transmitted 
image of the cells (scale bar: 10 µm). (B) The average trace shows the effects of 
ASNase (200 IU/ml) markedly induces [Ca2+]m elevation followed by 1 µM ACh (n = 
14). 
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Since we found that pre-incubation of pyruvate could reduce the mitochondria 
depolarization in pancreatic acinar cells, it is naturally to check the effect of 
pyruvate on [Ca2+]m dynamics induced by asparaginase. Freshly isolated 
pancreatic acinar cells were treated with pyruvate (1 mM) for 5 min, and then 
the same protocol, as it was done in Figure 4.5B, was used to monitor [Ca2+]m 
change. Figure 4.6A shows the pre-incubation of pyruvate markedly decrease 
the [Ca2+]m response induced by asparaginase (200 IU/ml) (n = 17, p < 0.01). 
ACh (1 μM) could elicit [Ca2+]m elevation when cells were treated with pyruvate, 
which is the major difference from the cells exposed to asparaginase without 
any treatment (Figure 4.5B).  
 
Mitochondrial Ca2+ is essential for the regulation of the metabolism, because 
they modulate dehydrogenases (191,419). Accumulated evidences suggest 
that pancreatic acinar cell death is an ATP dependent process (133,134). 
Galactose is a monosaccharide sugar that is converted via the Leloir pathway 
to glucose 6-phosphate (420) and finally is metabolized to pyruvate via the  
glycolytic pathway. Thus galactose enters glycolysis bypassing hexokinase at 
a slower rate than glucose (421). Since the protective effect of pyruvate has 
been found in our experiments, we next tested whether galactose exerts the 
same effect as pyruvate does in pancreatic acinar cells when challenged by 
asaparginase. To examine this, the same protocol was applied in this trial. 
Freshly isolated cells were pre-incubated with galactose (1 mM) for 15 min and 
then were exposed to asparaginase (200 IU/ml). As shown in Figure 4.6B, 
although small [Ca2+]m plateau with mitochondrial Ca
2+ transient developed in 
Rhod-2 loaded cells, pre-incubation of galactose significantly decrease the 
[Ca2+]m response induced by asparaginase (200 IU/ml) followed by ACh 
responses at the end of experiments (n = 6, p < 0.01). Figure 4.6C 
summarizes the degree of inhibition, caused by pre-incubation of pyruvate or 
galactose of the integrated mitochondrial Ca2+ signals evoked by 
asparaginase. 
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Figure 4.6 Pyruvate or galactose reduces mitochondrial Ca2+ response induced 
by asparaginase. 
The average traces show the effect of asparaginase (200 IU/ml) on mitochondrial 
calcium response are significantly decreased by 5 min preincubation of 1 mM 
pyruvate (A, n = 17) or 15 min preincubation of 1 mM galactose (B, n = 6) in 
pancreatic acinar cells. Quantitative analysis of experiments of the type shown in 
Figure 4.5A and B by comparing the integrated mitochondrial calcium change above 
the baseline (area under the curve) recorded during the first 1000 sec of 
asparaginase application (C; p < 0.01 for all cases). Bars represent mean ± SEM. 
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As mentioned previously, Ca2+ entry is extremely important for physiology as 
well as pathophysiology of pancreatic acinar cells (50). To investigate whether 
extracellular Ca2+ contributes to asparaginase-induced [Ca2+]m response in 
pancreatic acinar cells, we removed external Ca2+ in the buffer and applied 
asparaginase (200 IU/ml) to Rhod-2 loaded cells. As shown in Figure 4.7A, the 
much slower [Ca2+]m elevation was observed in first 10 min when compare with 
the experiments done with 1 mM external Ca2+ shown in Figure 4.5B (n = 10, p 
< 0.01; Figure 4.7B). 
 
Mitochondrial Ca2+ efflux is mainly regulated by mitochondrial Na+/Ca2+ 
exchanger, which is together with mitochondrial Ca2+ uniporter control the 
mitochondrial Ca2+ homeostasis (422,423), oxidative phosphorylation (424), 
and Ca2+ crosstalk among mitochondria, cytoplasm, and the ER (425). Here 
we examined the effect of mitochondrial Na+/Ca2+ exchanger – CGP-37157 
(251,426) in our experiments. Pre-incubation of CGP-37157 (20 μM) for 100 s 
could practically block mitochondrial Ca2+ extrusion and application of ACh (1 
μM) did not elicit further mitochondrial Ca2+ response (n = 6; Figure 4.8). 
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Figure 4.7 External Ca2+ accelerates [Ca2+]m plateau induced by asparaginase. 
(A) The average trace shows effects of ASNase (200 IU/ml) in the absence of 
extracellular Ca2+ followed by 1 µM ACh on mitochondrial calcium (n = 10). (B) Bar 
chart comparing first 10 min of the mitochondrial calcium change in the presence of 
calcium (red bar; Figure 4.5B) or absence of external calcium (blue bar), p < 0.01.  
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Figure 4.8 Na+/Ca2+ exchanger inhibitor CGP-37157 facilitates [Ca2+]m plateau 
induced by asparaginase. 
The average trace shows asparaginase (200 IU/ml) elicits the plateau on 
mitochondrial calcium with 100 sec treatment of mitochondrial Na+/Ca2+ exchanger 
inhibitor CGP-37157 (20 µM) followed by 1 µM ACh (n = 6). 
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Asparaginase affects glucose metabolism in 
pancreatic acinar cell 
Glucose is converted into pyruvate by the metabolic pathway called glycolysis. 
As the results shown above, it has been found that pyruvate was quite 
effective against mitochondrial ATP depletion. Also, galactose has been shown 
to reduce [Ca2+]m elevation induced by asparaginase significantly. Based on 
these evidences, we speculated that glucose metabolism can be affected by 
asparaginase. To test this hypothesis, we carried out experiments by using 
permutation and combination for glucose and pyruvate in extracellular solution. 
We found that pre-incubation of pyruvate (1 mM) for 5 min with or without 
glucose (10 mM) substantially reduced increasing of MgGreen fluorescence 
intensity compared with the cells in the absence of pyruvate in external 
solution (Figure 4.9A). Comparison of the response area (area under the curve; 
Figure 4.9B) and the amplitude of the traces at 2000 s (Figure 4.9C) were 
shown in the presence of pyruvate (1 mM) had more protection against ATP 
depletion than the cells was not treated with pyruvate. These results indicated 
that the metabolic pathway from glucose to pyruvate is interfered by 
asparaginase. 
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Figure 4.9 Pyruvate effectively protects against ATP depletion induced by 
asparaginase. 
(A) Cellular ATP was assessed by using MgGreen fluorescence. Average traces show 
ASNase (200 IU/ml) markedly increased [Mg2+]i in the absence of pyruvate (1 mM) 
when extracellular glucose (10 mM) was presence (purple trace, n = 21) or absence 
(red trace, n = 17). In contrast, pancreatic acinar cells exposure to pyruvate (1 mM) 
significantly decreased [Mg2+]i induced by ASNase (200 IU/ml) when extracellular 
glucose (10 mM) was presence (blue trace, n = 14) or absence (green trace, n = 16). 
(B) Quantitative analysis of experiments shown in A by comparing the cellular ATP 
depletion above the baseline (area under the curve). Pyruvate (blue bar and green 
bar) is highly effective against cellular ATP depletion induced by asparaginase (purple 
bar and red bar), p < 0.0001. (C) Bar chart comparing amplitude at 2000 s shown in A. 
In the absence of pyruvate, the amplitude is higher than the presence of pyruvate 
induced by ASNase in pancreatic acinar cells, p < 0.0001. 
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In order to investigate the phenomenon further that we observed above, two 
different sugars – fructose and galactose were applied in the study. Firstly, we 
tested ATP dynamic changes without extracellular glucose in pancreatic acinar 
cells. Figure 4.10 shows that ATP gradually and slowly was reduced inside the 
pancreatic acinar cells when glucose was not provided in the external solution. 
Therefore, glucose was replaced by pyruvate (10 mM), fructose (10 mM) or 
galactose (10 mM) in the buffer for freshly isolated cells and all cells were 
incubated with pyruvate, fructose or galactose for 1 hour before the additional 
of asparaginase (200 IU/ml). We found that cells treated with pyruvate (green 
trace, n = 19; Figure 4.11A), fructose (blue trace, n = 33; Figure 4.11A) or 
galactose (purple trace, n = 16; Figure 4.11A) substantially reduced ATP 
depletion compared with the cells exposed to glucose (red trace, n = 22; 
Figure 4.11A). The areas of responses are compared in Figure 4.11B, which 
shows the fully substitution of glucose by pyruvate, fructose or galactose could 
diminish a reduction in the intracellular ATP level induced by asparaginase in 
pancreatic acinar cells (p < 0.001).  
 
In the other protocol, pyruvate (1 mM), fructose (1 mM) or galactose (1 mM) 
was supplemented in the extracellular solution with glucose (10 mM) for freshly 
isolated cells. When these cells are exposed to asparaginase (200 IU/ml), the 
cells treated with pyruvate (green bar, n = 14; Figure 4.11C), fructose (blue bar, 
n = 9; Figure 4.11C) or galactose (purple bar, n = 16; Figure 4.11C) exerts the 
similar effect as 10 times concentration of them did on cellular ATP level 
changes. In other words, pyruvate (1 mM), fructose (1 mM) or galactose (1 mM) 
effectively reduces ATP depletion induced by asparaginase (p < 0.05). 
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Figure 4.10 ATP depletion induced by the absence of extracellular glucose in 
pancreatic acinar cells. 
Average trace shows [Mg2+]i change in the absence of glucose within 1 h followed by 
ATP depletion cocktail of CCCP (4 µM), oligomycin (10 µM) and sodium iodoacetate 
(2 mM) (n = 14). 
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Figure 4.11 Pyruvate, fructose or galactose reduces ATP depletion caused by 
asparaginase in pancreatic acinar cells. 
(A) Average traces show fully substitution of extracellular 10 mM glucose with 10 mM 
pyruvate (green trace, n = 19), 10 mM fructose (blue trace, n = 33) or 10 mM 
galactose (purple trace, n = 16) for 1 hour in pancreatic acinar cells could also highly 
against [Mg2+]i change induce by asparaginase (200 IU/ml) (red trace, n = 22). (B) 
Quantitative analysis of experiments of the type shown in A by comparing the 
integrated [Mg2+]i change above the baseline (area under the curve) recorded during 
the 30 min of ASNase application.(p < 0.001 for all cases). (C) Quantitative analysis of 
experiments for the additional of 1 mM pyruvate (n = 14), 1 mM fructose (n = 9) or 1 
mM galactose (n = 16) in external solution by comparing the integrated [Mg2+]i change 
above the baseline (area under the curve) recorded during the 30 min of ASNase 
application.(p < 0.05 for all cases). 
 
 
 
 
0
200
400
600
800
A
re
a
 u
n
d
e
r 
th
e
 c
u
rv
e
, 
a
.u
.
n.s.
ASNase
1 mM Pyruvate
ASNase
Fructose
ASNase
Galactose
ASNase
161 
 
As previously mentioned, ATP metabolism is highly related to Ca2+ signalling in 
pancreatic acinar cells (97,178,184,195). Since the effect of both pyruvate and 
galactose has been identified that they are protective for ATP reduction 
induced by asparaginase, thereafter we examined whether pyruvate or 
galactose could modulate asparaginase elicited aberrant Ca2+ signals. 
Pre-incubation of pyruvate (1 mM) for 5 min (n = 33; Figure 4.12B and D) or 
galactose (1 mM) for 15 min (n = 17; Figure 4.12C and D) eliminated 
asparaginase (200 IU/ml)-induced sustained [Ca2+]i
 elevation (n = 35; Figure 
4.12A and D) in Fluo-4 loaded pancreatic acinar cells. Figure 4.12E 
summarizes comparisons of the integrated responses (‘areas under the curve’ 
from the start of the responses until 30 min) showing that pyruvate or 
galactose significantly reduced the responses to asparaginase (p < 0.001 for 
both treatments). 
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Figure 4.12 Pyruvate or galactose reduces [Ca2+]i responses to asparaginase in 
pancreatic acinar cells. 
Measurements of the cytosolic calcium were performed using the fluorescence 
probes Fluo-4-AM. Asparaginase (200 IU/ml) elicits an elevated [Ca2+]i plateau with 
repetitive Ca2+ transients on top of the plateau in practically all cases (n = 35; A). The 
trace shows Pancreatic acinar cells were pre-incubated with pyruvate (1 mM) for 5 
min (n = 33; B) or galactose (1 mM) for 15 min (n = 17; C), there is no elevated [Ca2+]i 
plateau in the majority of cases. Average traces (D) show the changes in [Ca2+]i in 
response to ASNase (200 IU/ml) in the presence of pyruvate (1 mM) or galactose (1 
mM). Bar chart (E) comparing first 30min of the [Ca2+]i change in presence of pyruvate 
(blue bar) or galactose (green bar) in respond to ASNase (200 IU/ml) (red bar). (p < 
0.001 for both treatments). 
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We finally tested pyruvate, fructose and galactose in cell necrotic assay on 
pancreatic acinar cells. Figure 4.13A shows representative images of some of 
the treated cells as well as the results of PI staining. It is seen that 
asparaginase (200 IU/ml)-induced pancreatic acinar necrosis is stimulated 
with strong intracellular PI staining. In contrast, the treatment groups are not 
stained by PI. As seen in Figure 4.13B, in the absence of extracellularl glucose, 
asparaginase (200 IU/ml) induced the comparable level of necrosis (18.4 ± 0.2% 
of cells) to the group treated with asparaginase (200 IU/ml) in the presence of 
glucose (16.6 ± 0.3% of cells, p = 0.48). Replacement of external glucose with 
pyruvate (10 mM), fructose (10 mM) or galactose (10 mM) substantially 
reduced the level of asparaginase-induced necrosis close to the control level 
(p < 0.001). Furthermore, pyruvate (1 mM), fructose (1 mM) or galactose (1 
mM) was supplemented in the standard buffer for freshly isolated cells and 
then all cells were treated with asparaginase (200 IU/ml). As shown in figure 
4.13C, additional of pyruvate (1 mM), fructose (1 mM) or galactose (1 mM) 
significantly protected against asparaginase-induced necrosis. 
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Figure 4.13 Pyruvate, fructose or galactose protects against 
asparaginase-induced pancreatic acinar necrosis. 
(A) Representative images of cells from some of the experiments shown in (B and C). 
PI-stained fluorescence images (upper row) and transmitted light images (lower row). 
(B) The level of necrosis induced by 200 IU/ml of ASNase (16.6 ± 0.3%, three series 
with n > 300) is similar to the absence of glucose in pancreatic acinar cell induce by 
ASNase (18.4 ± 2.2%, three series with n > 300), p = 0.48. Whereas, fully substitution 
of extracellular 10 mM glucose with 10 mM pyruvate (5.6 ± 0.6%, three series with n > 
300, p < 0.001), 10 mM fructose (6.7 ± 1.1%, three series with n > 300, p < 0.001) or 
10 mM galactose (7.1 ± 1.1%, three series with n > 300, p < 0.001) markedly protect 
against necrosis to the control level (3.8 ± 0.6%, three series with n > 300). (C) In the 
presence of 1 mM pyruvate (5.4 ± 0.5%, three series with n > 300, p < 0.001), 1 mM 
fructose (5.4 ± 0.3%, three series with n > 300, p < 0.001) or 1 mM galactose (6.5 ± 
0.7%, three series with n > 300, p < 0.001) could also reduce the necrosis level induce 
by 200 IU/ml of ASNase (17.5 ± 0.4%, six series with n > 300).  
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Discussion 
The findings presented in this chapter provide the first mechanistic insights into 
both mitochondrial function and glucose metabolism are affected by 
asparaginase. Our data demonstrate that asparaginase lead to mitochondrial 
depolarization and sustained [Ca2+]m elevation, which are consistent with the 
results showing ATP reduction caused by asparaginase. Pre-incubation of 
pyruvate resulted in reduction of mitochondrial membrane potential and 
[Ca2+]m changes as well as pancreatic acinar necrotic cell death pathway 
activation when pancreatic acinar cells exposed to asparaginase, which 
indicates that energy supplement may protect against asparaginase-induced 
pancreatic acinar cell death.  
 
Interestingly, extracellular glucose and pyruvate used by the manner of 
permutation and combination demonstrate that glycolysis pathway in 
pancreatic acinar cells is disrupted by asparaginase, and subsequently fully 
substitution of pyruvate, fructose and galactose or additional of these three 
energy supplement confirmed that glucose metabolism via glycolysis is 
interfered by asparaginase. Furthermore, asparaginase-induced cytosolic Ca2+ 
overload is weakened by pre-incubation of pyruvate or galactose, which is 
together with the data showing that treatment with pyruvate, fructose and 
galactose significantly protect against pancreatic acinar necrosis suggest that 
the AAP patients can benefit from such treatment. However, whether there 
would be protective effects of this treatment in in vivo models remains to be 
determined. This is described in next chapter. 
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Chapter 5 
 
In vivo model of 
asparaginase-induced acute 
pancreatitis 
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Overview of asparaginase-associated pancreatitis 
Patients suffering from acute lymphoblastic leukaemia (ALL) who are receiving 
asparaginase treatment can develop acute pancreatitis, which is defined as 
asparaginase-associated pancreatitis (AAP) (290). This is the most common 
complication of the asparaginase treatment in childhood ALL (427–431). No 
matter what the preparation is, or dosage and ways of administration of 
asparaginase, the incidence of AAP remains unchanged 
(289,293,296,432,433). The incidence of AAP according to the retrospective 
studies is 5-10% of cases (289,291–293,296,432,434,435).  
 
The pathogenesis and pathophysiology underlying the development of AAP so 
far is still elusive. Genetic predispositions are likely to play a role in AAP. It has 
been reported that the CPA2 gene encoding carboxypeptidase A2 in human 
(436) and eukaryotic initiation factor 2 (eIF2) kinase, general control 
nonderepressible 2 (GCN2) in mouse (437) are highly related to AAP. Despite 
of the genetic risk factors, independent risk factors for AAP during ALL 
treatment include older age, higher exposure to asparaginase, combination 
therapy with other anti-cancer drugs and higher Native American ancestry 
(436).  
 
The study described in this chapter was designed to investigate the effects of 
asparaginase on experimental AP in vivo and evaluate the effects of two 
different therapies by using galactose in experimental AP. 
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A novel in vivo model of asparaginase-induced acute 
pancreatitis 
To establish a novel in vivo model of asparaginase-associated pancreatitis - 
ASNase-AP, C57BL/6J mice given four daily injections of recombinant 
Escherichia Coli L-asparaginase (Abcam) in sterile phosphate-buffered saline 
(PBS) at 20 IU/g. Animals received injections at the same time each day and 
were humanely sacrificed 24 h after the final injection. We observed that 
intraperitoneal injections of asparaginase (20 IU/g) induced pancreatic 
damage in histological slices taken 24 h after the final application, with 
extensive acinar cell edema, neutrophil infiltration and necrosis (Figure 5.1). 
Whereas in control group, mice also received four daily intraperitoneal 
injections of the same volume of PBS and the histological slices did not show 
any apparent histopathological changes (Figure 5.1). 
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Figure 5.1 Typical histopathology from ASNase-AP. 
Representative histological images of hematoxylin-eosin (H&E)-stained pancreatic 
acinar tissue sections show low magnification (x200, Scale bar: 50 μm; upper row) 
and high magnification (x400, Scale bar: 20 μm; lower row) of normal pancreatic 
histology and typical histopathology from ASNase-AP. ED, edema; N, necrosis; INF, 
inflammation. 
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Potential treatments for ASNase-AP 
As glucose metabolism affected by asparaginase were found in the in vitro 
study (Figure 4.9), herein, galactose was tested in mouse models of 
ASNase-AP to evaluate its effect in vivo. We designed two different manners 
of the treatments. In the first treatment group, mice were orally fed by water 
with galactose (180 mg/kg/day). In the other treatment group, galactose (180 
mg/kg/day) was administered intraperitoneally prior to asparaginase injection 
for the mice. Water containing galactose (10 mM) was also supplied daily for 
this group. Both ways of administration of galactose were protective on 
pancreatic histopathology (Figure 5.2), showing significant reduction of edema, 
inflammatory infiltration, necrosis and histopathology scores (p < 0.01; Figure 
5.3). 
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Figure 5.2 Typical histopathology of ASNase-AP following galactose feeding 
(Gal F) or feeding+injections (Gal F&I). 
Representative histological images of hematoxylin-eosin (H&E)-stained pancreatic 
acinar tissue sections show low magnification (x200, Scale bar: 50 μm; upper row) 
and high magnification (x400, Scale bar: 20 μm; lower row) of typical histopathology 
from ASNase-AP with treatments of either oral feeding of galactose (Gal F) or oral 
feeding of galactose with once intraperitoneal injection of galactose (Gal F&I).   
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Figure 5.3 Histopathological scores from ASNase-AP.  
ASNase-AP results in substantial increase in (A) histology score (B) edema, (C) 
inflammation, and (D) necrosis. Oral feeding of galactose (Gal F) or oral feeding of 
galactose with once intraperitoneal injection of galactose (Gal F&I) significantly 
reduced pancreatic damage, approaching control levels (mean ± SEM, ≥5 mice/group; 
**p < 0.01). Box-and-whisker plots indicate the median (line), mean (cross), IQR (box), 
and whiskers (min to max) in all figures. 
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Discussion 
The findings presented in this chapter provide a novel in vivo model of 
asparaginase-associated pancreatitis - ASNase-AP. The data demonstrated 
both orally feeding with and intraperitoneal administrations of galactose (180 
mg/kg/day) together significantly reduced a broad range of histopathological 
parameters in ASNase-AP. These findings are consistent with previous 
findings in vitro that galactose can attenuate effect of asparaginase–induced 
calcium overload, ATP loss and necrosis in pancreatic acinar cells (Chapter 2). 
Although both treatments did not decrease all histopathological parameters to 
the control level, these data nevertheless have very strong clinical implication 
and provide preclinical validation of energy supplement by galactose as a 
therapeutic approach for treating ASNase-AP. 
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Chapter 6 
 
Conclusions and general 
discussion 
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Summary 
 
L-Asparaginase is an essential element in the successful treatment of Acute 
Lymphoblastic Leukaemia (ALL), the most common type of cancer to affect 
children. However, asparaginase treatment can result in acute pancreatitis 
(AAP). This occurs in about 5–10% of cases and AAP is the most frequent 
cause of having to discontinue asparaginase treatment. Acute pancreatitis is a 
dangerous human disease characterized by premature activation of digestive 
enzymes inside the pancreatic acinar cells that leads to high levels of necrosis, 
digestion of the pancreatic tissue and its surroundings with no specific therapy. 
This study aims to investigate the molecular mechanisms underlying the 
development of AAP. Understanding the pathogenesis of AAP could lead to 
effective therapies for this complication, potentially reducing toxicity and 
allowing re-exposure to continued treatment with asparaginase. 
 
Confocal microscopy was used to investigate in vitro asparaginase-induced 
pathophysiological changes in cytosolic calcium, mitochondrial potential and 
calcium, ATP loss and necrosis. Both pharmacological inhibition of protease 
activated receptor 2 (PAR2) or calcium entry with GSK-7975A reduced calcium 
overload and necrosis in pancreatic acinar cells. Moreover, energy 
supplements i.e. adding pyruvate, fructose or galactose as a source of ATP 
had significantly reduced calcium signals, mitochondrial depolarization, 
mitochondrial calcium responses, ATP depletion and necrosis. We further 
developed the novel animal model of asparaginase-induced acute pancreatitis 
(i.e. intraperitoneal injections of asparaginase) and compared these protective 
effects followed by comparison of histological analysis. 
 
We conclude that combining inhibition of calcium overload with energy 
supplements could be potentially beneficial for AAP treatments. 
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General discussion 
 
In humans, the pancreas is the central and highly interconnected organ acting 
on both exocrine and endocrine functions, which is associated with the 
digestive and endocrine systems for normal physiological activity of 
metabolism. However, the pancreas is not only the target but also the effector 
critically involved in local and systemic inflammation. Pancreatic disorders 
including acute and chronic pancreatitis and pancreatic cancer are the main 
and fatal gastrointestinal diseases, which significantly affect the health of all 
mankind and reduce patients’ quality of life (200,201). The incidence of acute 
pancreatitis accounts for a large proportion in pancreatic diseases and even in 
gastrointestinal diseases. According to the epidemiological investigation, the 
annual incidence of acute pancreatitis (AP) affects up to 420 patients per 
million populations and has a 5 % mortality rate even in mild cases (195,205). 
The number of admissions and discharges with AP as principal diagnosis have 
increased by up to 30% over the last ten years (192,193). AP is undoubtedly 
the most common and the leading cause of hospital admissions for GI 
disorders, which costs approximately $2.63 billion per year (200). This is 
absolutely a source of substantial burden and cost for medical care of the 
society. Hence, the development of treatments for AP conducted by both 
laboratory and clinical studies is the best strategy to meet the challenge of this 
disease. 
 
Acute pancreatitis is a dangerous human disease characterized by premature 
activation of digestive enzymes inside the pancreatic acinar cells that leads to 
high levels of necrosis, digestion of the pancreatic tissue and its surroundings 
with no specific therapy (138). Repeated attacks of AP, in particular 
alcohol-related pancreatitis, may result in the development of chronic 
pancreatitis, which is likely to contribute to develop pancreatic cancer 
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(194,195). Obviously, these pancreatic disorders have seriously endangered 
human health. There is currently no specific drug to treat AP clinically. 
Therefore, there is pressing need to understand the mechanisms underlying 
AP and identify the potential biological target for the treatment of AP. This 
could prevent the recurrence of AAP and the possible transition from acute to 
chronic pancreatitis and pancreatic cancer. 
 
Asparaginase is the anti-leukaemic drug, forming an essential component of 
combination chemotherapy for the treatment of acute lymphoblastic leukaemia 
(ALL) in most young leukaemia patients (282). ALL is the most commonly 
diagnosed childhood cancer, accounting for 26% and 8% of cancers 
diagnosed in children and adolescents, respectively (438). During the last few 
decades, it has been demonstrated and supported by extensive clinical trials 
that intensive asparaginase treatment in pediatric ALL has dramatically 
improved of the long-term survival of ALL patients (272,282,285,439,440). 
However, in 5% to 10% of pediatric patients the asparaginase treatment has to 
be truncated due to development of acute pancreatitis (289,293,441). 
Asparaginase-associated pancreatitis (AAP) occurs after one or a few 
administrations of asparaginase. Re-exposure to asparaginase after the 
occurrence of AAP is associated with a high risk of recurrence. In this situation, 
further treatment of asparaginase is often discontinued, which may negatively 
impact event-free survival. The pathogenesis and pathophysiology underlying 
AAP is completely unknown.  
 
Evolutionally, various forms of life existed on Earth employ calcium ions (Ca2+) 
and adenosine triphosphate (ATP) to maintain the most basic living activity and 
control life, death and cellular signalling (180,442,443). These two molecules 
are profoundly interconnected and interdependent. This is because a low 
cytosolic Ca2+ concentration ([Ca2+]i) is required by ATP metabolism. In order 
to maintain such [Ca2+]i, the Ca
2+ signalling system using the immense 
181 
 
transmembrane Ca2+ gradients utterly demand ATP-dependent Ca2+ transport 
(444). Therefore, these two molecules are tethered together to regulate 
multiple vital functions. 
 
Ca2+ is a ubiquitous intracellular signal, which has been known for decades of 
its importance in controlling secretion. Under physiological stimulations, 
changes of [Ca2+]i results in cellular responses of molecular cascades. 
However, aberrant Ca2+ signalling contributes to numerous diseases including 
pancreatitis, cardiovascular disease and nervous system disorders 
(236,445,446). In pancreatic acinar cells, physiological Ca2+ signals consist of 
repetitive [Ca2+]i spikes and often these are confined to the apical pole. Local 
Ca2+ signalling induced by physiological concentration of ACh or CCK can only 
be transient, whereas sustained [Ca2+]i elevations evoked by pathological 
stimuli (combinations of alcohol and fatty acids or bile acids) always become 
global and lead to inflammation of the pancreas. The latter pattern of Ca2+ 
signals is toxic, because intracellular Ca2+ overload not only invades some 
sub-cellular spaces where only requires local Ca2+ regulation, but also 
decrease mitochondrial ATP production due to depolarization of the inner 
mitochondrial membrane caused by opening of the MPTP (447). Cytosolic 
Ca2+ overloading initiates negative event loop that overloading of mitochondria 
with Ca2+ reduce markedly in mitochondrial ATP synthesis will affect Ca2+ 
pumps and prevent Ca2+ movements across the plasmalemma and the 
endomembranes, which eventually cause further [Ca2+]i elevation. 
 
The aims of this thesis were to understand the mechanism underlying the 
asparaginase-associated pancreatitis (AAP). Moreover, we have also explored 
potential molecular therapeutic targets. We further aimed to develop 
therapeutic approaches by using novel in vivo mouse model of AAP to probe a 
new effective treatment for AAP.  
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Effects of asparaginase on calcium signalling in 
pancreatic acinar cells 
Intracellular Ca2+ plays a critical role in the initiation of acute pancreatitis. The 
process of this disease is Ca2+ dependent, in which digestive proenzymes are 
prematurely activated inside the pancreatic acinar cells causing necrosis of 
acinar cells and autodigestion of pancreatic tissue (138,202,448). Studies on 
isolated murine cells or cell clusters are enormously useful methods in 
understanding AP (312,354,371,449). Furthermore, results obtained from in 
vitro experiments have turned out to predict accurately the outcome of in vivo 
studies of real AP (351–354). Hence, acute studies of the effects of 
asparaginase on isolated mouse acinar cells or cell clusters was our approach, 
for the first time, to investigate the mechanism of AAP. However, time course is 
one of the challenges inherent in this approach. This is because the time 
course needed in the clinical situation for the development of AAP typically 
requires several weeks after a few administration of asparaginase (290), which 
is quite different from the time course needed for in vitro study to observe the 
effects of asparaginase on normal freshly isolated acinar cells within hours .  
 
The results presented in this thesis indicate that Ca2+ overload is the critical 
trigger in the pathophysiology of AAP and is responsible for 
asparaginase-elicited pancreatic acinar injury. This probably can explain the 
development process of AAP, which share some similarities with AP induced 
by fatty acid ethyl esters (FAEE) as well as bile acids (134,136,138). 
Asparaginase generate toxic Ca2+ signals by eliciting Ca2+ release from 
intracellular stores and then followed by store-operated Ca2+ entry through 
CRAC channels. However, the sustained [Ca2+]i elevations evoked by FAEE or 
bile acids are somewhat larger than that induced by asparaginase. This is 
consistent with our results shown that the level of necrosis induced by 
asparaginase is somewhat lower than that caused by the alcohol metabolite 
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POAEE or the bile acid taurolithocholic acid 3-sulfate (TLC-S).  
 
In pancreatic acinar cells, IP3R types 2 and 3 are predominantly expressed in 
the apical region and responsible for physiological Ca2+ signalling and enzyme 
secretion (69,450). IP3Rs-mediated excessive Ca
2+ release from intracellular 
stores is evoked by various stimuli such as supramaximal dose of CCK, FAEE 
and TLC-S. This effect could be inhibited by double knockout of IP3Rs (451). 
Our data show that the intracellular messengers IP3 and the intracellular 
receptors IP3Rs are involved in asparaginase-induced Ca
2+ release from 
intracellular stores, which is due to activation of a signal transduction 
mechanism via G-protein–coupled protease-activated receptor 2 (PAR2). 
Despite the fact that the importance of PAR2 activation in triggering 
inflammatory responses has been well defined, the signal transduction 
mechanisms involved in PAR2-mediated mobilization of cytosolic Ca2+ and 
effector responses remain to be unraveled (345,376). Blocking PAR2 by 
selective antagonist FSLLRY-NH2 alleviated asparaginase-evoked cytosolic 
Ca2+ overload and blocking muscarinic receptor by nonselective antagonist 
atropine did not affect pathological Ca2+ response stimulated by asparaginase. 
Together with the data showing that FSLLRY-NH2 had no effect on muscarinic 
receptor, our results suggest that asparaginase-induced [Ca2+]i elevations is 
elicited via PAR2. Although the results indicate that PAR2 is linked to the 
development of AAP, it is still not fully understood how PAR-2 activation drive 
inflammatory responses in acinar cells, which is associated with pancreatic 
acinar necrosis. Interestingly, it has been recently reported that 
PAR2-activated Ca2+ signalling and cytokine production are regulated by 
CRAC channels in human airway epithelial cells (452). We may speculate that 
stimulation of PAR2 by asparaginase triggers opening of CRAC channels in 
pancreatic acinar cells, in turn, leads to the release of numerous inflammatory 
mediators. More studies using knockout mice would be needed to test this 
issue. 
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Ca2+ entry plays a critical role in the formation of the pathologically elevated 
[Ca2+]i plateau in pancreatic acinar cells and is crucial for the initiation of acinar 
cell injury (312). Removal of external Ca2+, adding Ca2+ chelator EGTA in 
buffer or pharmacological CRAC blockade by GSK-7975A show the sustained 
[Ca2+]i elevations induced by asparaginase are markedly reduced. These 
results confirm Ca2+ entry is indispensable and responsible for Ca2+ overload 
and CRAC channels are involved in the pathophysiological process of AAP. 
The specific CRAC channel blocker GSK-7975A markedly reduces the 
asparaginase-evoked sustained [Ca2+]i plateau, which is consistent with the 
previous finding that the main pathway of store-operated Ca2+ influx and Ca2+ 
entry currents is CRAC channel (312) rather than transient receptor potential 
(TRP) channel (453,454) in pancreatic acinar cells. Nevertheless, Ca2+ entry 
mediated by TRP channels, mainly by TRPC3, is contributed to the damage of 
the pancreas. Either genetic or pharmacological inhibition of TRPC3 showed 
protective effect to against pancreatic inflammatory responses (453,454). 
 
Based on a specific protocol routinely used to assess Ca2+ influx and efflux 
(312), we observed that asparaginase significantly affect both Ca2+ entry and 
extrusion in acinar cells. However, the slowing down of the rate of Ca2+ 
extrusion is quantitatively the most important effect of asparaginase on acinar 
cells. This indicates that intracellular ATP level of acinar cells is reduced by 
asparaginase treatment which, in turn, limits the energy supply to the Ca2+ 
ATPase in the plasma membrane (PMCA). It has been demonstrated that Ca2+ 
extrusion is mainly regulated by PMCA rather than NCX in the plasma 
membrane in pancreatic acinar cells (96,97) and the processes of Ca2+ across 
the plasma membrane is energy-dependent (99). Therefore, it is a strong 
implication that asparaginase could deplete cellular ATP in acinar cells. 
 
We further investigated the effect of asparaginase on mitochondrial Ca2+ 
handling. Mounting evidence suggests that mitochondria are extremely helpful 
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in regulating spatio-temporal patterns of intracellular Ca2+ signalling (455,456). 
Mitochondrial Ca2+ homeostasis is very complex. This is because numerous 
Ca2+ channels, pumps and exchangers are involved to regulate this dynamic 
process. It is not surprising that the result presented here shows asparaginase 
evoke prolonged elevation of [Ca2+]m in acinar cells. This is likely due to 
relatively fast Ca2+ uptake and slower Ca2+ extrusion by mitochondria so that 
[Ca2+]i transients
 can be blunted and transformed into long term [Ca2+]i 
elevations. Moreover, long lasting cytosolic Ca2+ overload is able to induce 
such effect in mitochondria of pancreatic acinar cells. Inhibition of the 
mitochondrial Na+/Ca2+ exchanger with CGP-37157 results in prolonged 
[Ca2+]m plateau, which indicate that the mechanism of Ca
2+ extrusion of 
mitochondria is mainly controlled by Na+/Ca2+ exchanger. This is consistent 
with the observation in another type of excitable cell — chromaffin cells (457). 
Interestingly, both pyruvate or galactose reduce asparaginase-induced [Ca2+]m 
response, which is implicated in metabolic demands for ATP production and 
energy expenditure in the cell. Mitochondrial Ca2+ uptake plays a crucial role in 
the modulation of cellular Ca2+ homeostasis and bioenergetics (458,459), 
thereby, it is necessary to conduct experiments on mitochondrial Ca2+ handling 
during the action of asparaginase for further studies. 
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Effects of asparaginase on ATP metabolism in 
pancreatic acinar cell 
ATP production via the metabolic pathways of glycolysis (Figure 6.1) and 
oxidative phosphorylation is critical for physiological functions of the pancreas 
(72,180,182). Calcium signalling machinery includes Ca2+ release from internal 
stores via IP3R and RyR, Ca
2+ entry from the extracellular solution via 
store-operated channels, Ca2+ uptake and Ca2+ extrusion by Ca2+ pumps. All 
components of this machinery are influenced by mitochondria and cellular ATP 
level. On the other hand, Ca2+ movement process is energy dependent and 
cellular Ca2+ homeostasis is associated with ATP dynamics. Accumulating 
evidence from past decades demonstrate that ATP is essential not only for 
secretion in pancreatic acinar cells, but also for pathogenesis of acute 
pancreatitis (133,134).  
 
Our data show that Ca2+ extrusion is significantly affected by the treatment of 
asparaginase in acinar cells. As the process of Ca2+ extrusion is 
ATP-demanding, therefore, we assessed asparaginase on intracellular ATP 
changes in pancreatic acinar cells. The results show that asparaginase 
markedly reduces the intracellular ATP levels and induces mitochondrial 
depolarization, which support the hypothesis that Ca2+ extrusion slowed down 
by asparaginase due to the reduction in the intracellular ATP level limit the 
energy supply to the PMCA.  
 
Pyruvate is a product of glycolysis. This chemical compound is efficiently 
imported and utilized by mitochondria to supply energy to cells through the 
Krebs cycle (460). Previous studies show the effects of pyruvate modulate 
Ca2+ signalling, which highlight another critical and clearly underexplored link 
between Ca2+-channel function and energy demand (461,462). The results 
presented here demonstrate that the asparaginase-induced ATP loss was 
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substantially reduced by the addition of pyruvate to pancreatic acinar cells. 
Moreover, the addition of fructose or galactose also exerts the similar effect as 
pyruvate in protecting against ATP loss. Further, replacing glucose with 
pyruvate, fructose or galactose in extracellular medium markedly reduce the 
ATP depletion evoked by asparaginase. These results indicate that 
supplement with energy source such as pyruvate, fructose and galactose 
could boost energy production in vitro to counteract the toxic effects of 
asparaginase. Our data also show that both pyruvate and galactose very 
markedly reduced the asparaginase-elicited [Ca2+]i rise and [Ca
2+]m elevation.  
Interestingly, we observed that the ATP loss was substantially higher in the 
absence of pyruvate regardless of the presence or absence of glucose. Taken 
these results together, it suggests that asparaginase may interrupt 
intermediary metabolism and hexokinase activity is inhibited by asparaginase. 
Therefore, hexokinase dysfunction could be the likely explanation of the ATP 
loss in AAP. To explore the potential effects of asparaginase affecting 
hexokinase activity will be the subject of follow-up studies. 
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Figure 6.1 Simplified schematic diagram of glycolysis.  
(Modified from Gatenby RA & Gillies RJ., Nat Rev Cancer. 2004) (463) 
The diagram shows the metabolic pathway of glycolysis. Both glucose and galactose 
can be transported into glycolysis pathway and eventually forms pyruvate in 
pancreatic acinar cells. 
 
 
 
 
 
 
 
 
189 
 
Potential targets and therapies for 
asparaginase-associated pancreatitis 
The clinical presentation and complications in asparaginase-associated 
pancreatitis (AAP) do not differ significantly from acute pancreatitis (AP) in 
other pediatric populations (290). Therefore, AAP can be diagnosed by the 
same diagnostic procedures as AP if at least two of the following three criteria 
are met: typical upper abdominal pain, serum amylase or lipase at least three 
times the upper limit of normal and confirmatory findings from cross-sectional 
imaging analysis (192,193,217). Although AAP can be monitored by clinicians, 
there is a lack of specific therapy for patients who developed AAP in the course 
of receiving asparaginase treatment. This also significantly affects 
re-administration of asparaginase after the occurrence of AAP, which 
dramatically decreases event-free survival in childhood ALL. Understanding 
the mechanisms underlying the development of AAP leads to the development 
of new therapeutic approaches for reducing the side-effects of asparaginase 
treatments. 
 
Current strategies for managing AP are supportive, which includes fluid 
resuscitation, analgesia and enteral nutritional support. However, these 
treatments do not deal with the root cause of the disease. The current 
consensus of the initiation step of AP is that intracellular proteases are 
activated inside the pancreatic acinar cell by toxic Ca2+ signals evoked by, for 
example, non-oxidative alcohol metabolites or bile acids (138,202,235). 
However, there are now opportunities for new therapeutic intervention based 
on recent advances in our understanding of Ca2+ handling and bioenergetics in 
pancreatic acinar cells of AAP. 
 
It is now clear that pancreatitis-inducing stimulants release Ca2+ from both the 
ER and acidic stores primarily via IP3 receptors and that the depletion of 
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internal Ca2+ stores causes opening of store-operated Ca2+ channels in the 
plasma membrane, mediating the sustained Ca2+ entry mainly by CRAC 
channel into the cells during prolonged stimulation of the pancreatic acinar 
cells (136). Cytosolic Ca2+ overload is a crucial feature of AP, thereby, inhibition 
of the primary Ca2+ release and Ca2+ entry, enhancement of Ca2+ extrusion are 
all attractive and potential targets for the treatment of AP. The results 
presented in this thesis demonstrate that AAP is owing to toxic Ca2+ signal 
generation and the primary site of asparaginase acting on pancreatic acinar 
cells seems to be PAR2. Accumulating evidence suggest that PAR2 has been 
most prominently implicated in the pathogenesis of AP, although its exact role 
is still debated (347–350). The controversy about the role of PAR2 in AP is due 
to the observation obtained from two pancreatitis models: bile salt-induced 
model and caerulein-induced model. In the bile salt-induced pancreatitis model, 
PAR2 activation triggers the pathological Ca2+ signals. Consequently, 
pancreatic injury become worse via a series of downstream events including 
acinar cell injury and c-Jun N-terminal kinase (JNK) activation (349). In 
contrast, PAR2 activation reduces the severity of pancreatic injury in 
caerulein-induced pancreatitis model by the similar mechanisms as the bile 
salt-induced pancreatitis model and by stimulating the secretion of activated 
digestive zymogens from acinar cells as well as by reducing the translocation 
of extracellular-signal regulated kinase (ERK)1/2, but this does not involve an 
alteration in the generation of [Ca2+]i elevation (348,350,464,465). Due to 
different responses observed in dissimilar models and in the absence of 
clinical studies, we believe that the induction of the clinical relevant model 
should direct interpretation of the results. Moreover, pharmacologic activation 
of PAR2 could trigger profound hypotension and activation of neutrophils and 
generation of IL-8, which contribute to the MODS (348). Interestingly, it has 
been reported that activation of PAR2 receptors stimulate neural pathways 
linked to pain in the pancreas (466,467). Our data indicate that blocking PAR2 
leads to the reduced level of asparaginase-elicited intracellular Ca2+ overload 
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and necrosis, which support the hypothesis that asparaginase-induced PAR2 
activation is the onset of AAP. These results are consistent with the studies in 
airway epithelial cells and the emerging idea that acute responses to PAR2 
tend to be protective largely, whereas more sustained responses to PAR2 
activation result in proinflammatory effect (452,468,469) and pain. From our 
perspective, we suggest that interventions designed to interfere with PAR2 
activation would favorably affect the outcome of AAP.  
 
Pancreatic acinar cell is the electrically non-excitable cell, which do not 
possess voltage-gated Ca2+ channels. Hence, CRAC channels constitute the 
main Ca2+ entry pathway and contribute to both physiological and pathological 
Ca2+ signalling in acinar cells. The previous studies show that CRAC channel 
inhibition both in vitro and in vivo by GSK-7975A dramatically reduces Ca2+ 
toxicity and effectively eliminates necrosis in pancreatic acinar cells (312,354). 
Here, our results indicate that asparaginase-induced pathological Ca2+ signals 
depend on CRAC-mediated Ca2+ entry are markedly inhibited by the CRAC 
channel blocker GSK-7975A and also that, consequently, 
asparaginase-induced necrosis and ATP loss are significantly reduced. CRAC 
channels are widely expressed in the body, thereby, there is an argument 
about CRAC inhibition as a potential treatment against, for example, asthma 
(470) or pancreatitis (240,312,313), because it is likely to occur unintended 
side-effects in the course of the treatment of CRAC blockade. Nevertheless, it 
has recently been demonstrated that inhibition of CRAC channels by 
GSK-7975A or CM_128 is the remarkably effective way to treat experimental 
pancreatitis in three different in vivo mouse models (354). CRAC channel 
inhibitors have mainly been designed and developed to deal with 
immunological disorders (369,370,471–475). Hence, they also inhibit Ca2+ 
entry into various immune cells such as neutrophils (476–478) invade and 
infiltrate pancreatic tissue in the early stages of AP, which exacerbate the 
development of this disease. In this situation, inhibition of immune cell 
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activation by blocking Ca2+ entry would be beneficial and advantageous to limit 
the inflammatory responses to the pancreas. Interestingly, pancreatic stellate 
cells have been implicated in the amplification the effects of 
pancreatitis-inducing agents (POAEE and bile acids) on the acinar cells 
(389,390,479,480). CRAC channel blockade would diminish toxic Ca2+ signal 
generation in both acinar and stellate cells, and this may explain the 
remarkable success of such inhibition in preventing pancreatic acinar injury in 
three experimental pancreatitis in vivo models. Although the primary 
intracellular Ca2+ release sites could be the potential target to be developed 
against AP (352,391), however, it may be more profitable to focus on 
store-operated Ca2+ entry channels as this would not necessarily consider 
about efficient delivery of drug into the cells. Clearly, future study would need 
to test the effectiveness of CRAC channel blocker in an in vivo AAP mouse 
model.  
 
In terms of bioenergetics in pancreatic acinar cells, we focused our 
investigations on the effects of galactose, an essential component of human 
breast milk (481), as this sugar has already been included as part of human 
trials for the treatment of the glycogen storage disease type 1b (Fabry’s 
disease), nephrotic syndrome, congenital disorders of glycosylation etc. and 
has not shown to have any negative effects (482–485). In view of the 
remarkable protective effects of galactose against asparaginase-induced 
intracellular toxic Ca2+ signals, ATP loss and necrosis from our results, we 
tested the effect of galactose in a novel in vivo AAP model. Galactose is quite 
stable in solution, relatively slowly metabolised as compared to pyruvate or 
fructose and has been used in both IV injection as well as feeding (drink) 
protocols (486–488). Our results show galactose markedly changed the 
histology score and the degrees of edema, inflammation and necrosis towards 
more normal values in both feeding and injection plus feeding protocols and 
with very similar efficiency. Therefore, potentially, galactose could become a 
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new effective treatment for AAP. 
 
Clearly, both Ca2+ and ATP play key roles in the pathophysiology of pancreatic 
disorder and therapeutic strategies should take both into account and must be 
based on Ca2+ transport systems and cellular bioenergetics. Overall, the 
findings present in this thesis indicate that inhibition of PAR2, CRAC channel 
blockade or boosting cellular energy production by administering galactose 
has the potential to become a valuable and effective therapy in the acute early 
stage of AAP (Figure 6.2).   
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Figure 6.2 Potential sites for therapeutic intervention of AAP.  
(Modified from Peng S et al, Philos Trans R Soc Lond B Biol Sci. 2016) (313) 
Schematic diagram illustrating the mechanisms of asparaginase-induced necrotic cell 
death pathway activation on pancreatic acinar cells and the potential drug targets for 
the treatment of AAP. 
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